https://priors.science/q/10-total-body-weight-loss-predicts-fibrosis-regression-in-nash 2026-07-17 weekly https://priors.science/q/177lu-psma-617-lutetium-vipivotide-tetraxetan-significantly-impro 2026-07-17 weekly https://priors.science/q/7-to-10-body-weight-loss-resolves-nash-in-obese-patients 2026-07-17 weekly https://priors.science/q/a-clinically-significant-proportion-of-individuals-experience-per 2026-07-17 weekly https://priors.science/q/a-minority-of-itp-patients-achieve-sustained-platelet-responses-o 2026-07-17 weekly https://priors.science/q/a-significantly-higher-proportion-of-people-with-type-2-diabetes 2026-07-17 weekly https://priors.science/q/a-stepwise-approach-initiating-a-single-prandial-insulin-injectio 2026-07-17 weekly https://priors.science/q/a-treat-to-target-strategy-targeting-minimal-disease-activity-imp 2026-07-17 weekly https://priors.science/q/a-treat-to-target-strategy-targeting-remission-or-low-disease-act 2026-07-17 weekly https://priors.science/q/a-universal-tumour-mutational-burden-cutoff-of-10-mutations-mb-is 2026-07-17 weekly https://priors.science/q/aav-mediated-exon-skipping-gene-therapy-produces-partial-restorat 2026-07-17 weekly https://priors.science/q/aav-mediated-gene-transfer-for-sarcoglycanopathy-subtypes-of-lgmd 2026-07-17 weekly https://priors.science/q/aav8-mediated-mtm1-gene-replacement-therapy-at132-improves-motor 2026-07-17 weekly https://priors.science/q/abatacept-and-rituximab-achieve-clinical-responses-comparable-to 2026-07-17 weekly https://priors.science/q/abatacept-reduces-mrss-in-early-diffuse-cutaneous-ssc 2026-07-17 weekly https://priors.science/q/abbreviated-dapt-reduces-bleeding-in-high-bleeding-risk-pci-patie 2026-07-17 weekly https://priors.science/q/abiraterone-acetate-plus-prednisone-significantly-improves-overal 2026-07-17 weekly https://priors.science/q/abrocitinib-achieves-rapid-itch-relief-in-moderate-to-severe-atop 2026-07-17 weekly https://priors.science/q/ace-inhibitor-discontinuation-does-not-benefit-advanced-ckd 2026-07-17 weekly https://priors.science/q/ace-inhibitors-improve-outcomes-in-established-scleroderma-renal 2026-07-17 weekly https://priors.science/q/ace-inhibitors-reduce-ckd-progression-in-proteinuric-kidney-disea 2026-07-17 weekly https://priors.science/q/ace-inhibitors-reduce-mortality-in-acs-with-reduced-ejection-frac 2026-07-17 weekly https://priors.science/q/acei-and-arb-withdrawal-during-heart-failure-hospitalisation-incr 2026-07-17 weekly https://priors.science/q/acei-and-arbs-facilitate-ejection-fraction-recovery-in-dilated-ca 2026-07-17 weekly https://priors.science/q/acei-and-arbs-provide-comparable-cardiovascular-event-protection 2026-07-17 weekly https://priors.science/q/acei-and-arbs-reduce-albuminuria-and-slow-diabetic-nephropathy-pr 2026-07-17 weekly https://priors.science/q/acei-and-arbs-reduce-all-cause-mortality-in-heart-failure-with-re 2026-07-17 weekly https://priors.science/q/acei-and-arbs-reduce-major-cardiovascular-events-in-high-risk-pat 2026-07-17 weekly https://priors.science/q/acei-and-arbs-slow-progression-of-proteinuric-chronic-kidney-dise 2026-07-17 weekly https://priors.science/q/acei-causes-persistent-dry-cough-in-5-to-20-percent-of-treated-pa 2026-07-17 weekly https://priors.science/q/acei-induced-angioedema-is-more-frequent-in-black-patients 2026-07-17 weekly https://priors.science/q/acei-induced-angioedema-typically-develops-after-months-to-years 2026-07-17 weekly https://priors.science/q/acei-monotherapy-is-associated-with-worse-cardiovascular-outcomes 2026-07-17 weekly https://priors.science/q/acei-plus-arb-combination-does-not-reduce-cardiovascular-mortalit 2026-07-17 weekly https://priors.science/q/acetazolamide-added-to-loop-diuretic-therapy-improves-natriuresis 2026-07-17 weekly https://priors.science/q/achievement-of-complete-renal-response-urine-protein-creatinine-0 2026-07-17 weekly https://priors.science/q/achieving-endoscopic-mucosal-healing-reduces-long-term-risk-of-di 2026-07-17 weekly https://priors.science/q/achieving-ldl-below-70-reduces-cardiovascular-events-in-advanced 2026-07-17 weekly https://priors.science/q/achieving-ldl-c-below-55-reduces-mace-more-than-below-70 2026-07-17 weekly https://priors.science/q/achieving-lupus-low-disease-activity-state-lldas-for-at-least-50 2026-07-17 weekly https://priors.science/q/achieving-transmural-healing-is-associated-with-superior-long-ter 2026-07-17 weekly https://priors.science/q/acoramidis-reduces-all-cause-mortality-and-cardiovascular-hospita 2026-07-17 weekly https://priors.science/q/acquired-c797s-mutation-in-egfr-exon-20-is-the-primary-mechanism 2026-07-17 weekly https://priors.science/q/acquired-t790m-mutation-mediates-resistance-to-first-and-second-g 2026-07-17 weekly https://priors.science/q/acute-exacerbations-carry-greater-than-50-90-day-mortality-in-ipf 2026-07-17 weekly https://priors.science/q/adagrasib-kras-g12c-inhibitor-demonstrates-meaningful-objective-r 2026-07-17 weekly https://priors.science/q/add-on-therapy-with-belimumab-or-anifrolumab-enables-glucocortico 2026-07-17 weekly https://priors.science/q/added-sugar-raises-diabetes-risk-independent-of-adiposity 2026-07-17 weekly https://priors.science/q/adding-a-glp-1-receptor-agonist-to-basal-insulin-improves-hba1c-a 2026-07-17 weekly https://priors.science/q/adding-abiraterone-acetate-plus-prednisone-to-androgen-deprivatio 2026-07-17 weekly https://priors.science/q/adding-enzalutamide-or-darolutamide-to-androgen-deprivation-thera 2026-07-17 weekly https://priors.science/q/adding-ici-to-perioperative-platinum-based-chemotherapy-improves 2026-07-17 weekly https://priors.science/q/adding-large-vessel-ultrasound-improves-diagnostic-sensitivity-in 2026-07-17 weekly https://priors.science/q/adding-memantine-to-cholinesterase-inhibitors-improves-outcomes-o 2026-07-17 weekly https://priors.science/q/adding-sodium-to-rehydration-fluid-improves-post-exercise-fluid-r 2026-07-17 weekly https://priors.science/q/adjuvant-abemaciclib-reduces-recurrence-in-high-risk-early-breast 2026-07-17 weekly https://priors.science/q/adjuvant-alectinib-improves-dfs-in-resected-alk-nsclc 2026-07-17 weekly https://priors.science/q/adjuvant-anti-pd-1-therapy-pembrolizumab-or-nivolumab-significant 2026-07-17 weekly https://priors.science/q/adjuvant-atezolizumab-bevacizumab-reduces-recurrence-after-hcc-re 2026-07-17 weekly https://priors.science/q/adjuvant-ipilimumab-reduces-recurrence-after-resection-of-stage-i 2026-07-17 weekly https://priors.science/q/adjuvant-nivolumab-after-radical-cystectomy-reduces-disease-recur 2026-07-17 weekly https://priors.science/q/adjuvant-nivolumab-benefit-in-muscle-invasive-urothelial-carcinom 2026-07-17 weekly https://priors.science/q/adjuvant-nivolumab-extends-disease-free-survival-compared-to-plac 2026-07-17 weekly https://priors.science/q/adjuvant-nivolumab-following-radical-cystectomy-improves-disease 2026-07-17 weekly https://priors.science/q/adjuvant-nivolumab-improves-relapse-free-survival-and-overall-sur 2026-07-17 weekly https://priors.science/q/adjuvant-osimertinib-significantly-improves-disease-free-survival 2026-07-17 weekly https://priors.science/q/adjuvant-oxaliplatin-reduces-recurrence-in-stage-iii-colon-cancer 2026-07-17 weekly https://priors.science/q/adjuvant-pembrolizumab-following-complete-resection-and-chemother 2026-07-17 weekly https://priors.science/q/adjuvant-pembrolizumab-following-nephrectomy-improves-disease-fre 2026-07-17 weekly https://priors.science/q/adjuvant-pembrolizumab-improves-recurrence-free-survival-compared 2026-07-17 weekly https://priors.science/q/adjuvant-pembrolizumab-improves-recurrence-free-survival-in-patie 2026-07-17 weekly https://priors.science/q/adjuvant-pembrolizumab-reduces-recurrence-after-hcc-resection-or 2026-07-17 weekly https://priors.science/q/adjuvant-trastuzumab-reduces-recurrence-in-her2-positive-early-br 2026-07-17 weekly https://priors.science/q/admilparant-slows-fvc-decline-in-ipf 2026-07-17 weekly https://priors.science/q/aducanumab-lacks-clinical-benefit 2026-07-17 weekly https://priors.science/q/aducanumab-provides-clinically-meaningful-benefit-in-alzheimer-s 2026-07-17 weekly https://priors.science/q/advanced-fibrosis-increases-all-cause-mortality-risk-3-fold-in-na 2026-07-17 weekly https://priors.science/q/advanced-fibrosis-persists-in-47-despite-nash-resolution-post-sur 2026-07-17 weekly https://priors.science/q/aerobic-exercise-reduces-migraine-frequency 2026-07-17 weekly https://priors.science/q/afp-serum-level-is-an-independent-prognostic-factor-for-hcc-survi 2026-07-17 weekly https://priors.science/q/aggregate-targeting-outperforms-monomer-targeting 2026-07-17 weekly https://priors.science/q/alcohol-consumption-increases-all-cause-mortality 2026-07-17 weekly https://priors.science/q/alcohol-consumption-increases-atrial-fibrillation-risk 2026-07-17 weekly https://priors.science/q/alcohol-consumption-increases-breast-cancer-risk 2026-07-17 weekly https://priors.science/q/alcohol-consumption-increases-colorectal-cancer-risk 2026-07-17 weekly https://priors.science/q/alcohol-consumption-increases-dementia-risk 2026-07-17 weekly https://priors.science/q/alcohol-consumption-increases-hypertension-risk 2026-07-17 weekly https://priors.science/q/alcohol-consumption-increases-overall-cancer-risk 2026-07-17 weekly https://priors.science/q/alcohol-consumption-worsens-depression 2026-07-17 weekly https://priors.science/q/alectinib-is-superior-to-crizotinib-as-first-line-treatment-for-a 2026-07-17 weekly https://priors.science/q/alk-inhibitors-are-effective-in-alk-anaplastic-large-cell-lymphom 2026-07-17 weekly https://priors.science/q/alk-kinase-domain-mutations-drive-resistance-to-second-generation 2026-07-17 weekly https://priors.science/q/alk-nsclc-harbors-an-immunosuppressive-tumor-microenvironment 2026-07-17 weekly https://priors.science/q/alk-tki-and-ici-combination-does-not-improve-outcomes-vs-tki-alon 2026-07-17 weekly https://priors.science/q/allopurinol-does-not-significantly-slow-ckd-progression-in-hyperu 2026-07-17 weekly https://priors.science/q/alopecia-areata-causes-high-rates-of-anxiety-and-depression 2026-07-17 weekly https://priors.science/q/alpelisib-plus-fulvestrant-extends-progression-free-survival-in-p 2026-07-17 weekly https://priors.science/q/alternate-day-fasting-combined-with-exercise-reduces-hepatic-fat 2026-07-17 weekly https://priors.science/q/alternate-day-oral-iron-improves-absorption-over-daily-dosing 2026-07-17 weekly https://priors.science/q/ambulatory-bp-monitoring-predicts-cv-outcomes-better-than-office 2026-07-17 weekly https://priors.science/q/amivantamab-egfr-met-bispecific-antibody-and-mobocertinib-provide 2026-07-17 weekly https://priors.science/q/amr-causes-over-one-million-deaths-annually 2026-07-17 weekly https://priors.science/q/amyloid-clearance-predicts-clinical-benefit 2026-07-17 weekly https://priors.science/q/amyloid-confirmation-required-before-treatment 2026-07-17 weekly https://priors.science/q/amyloid-pet-reduction-predicts-cognitive-benefit-in-anti-amyloid 2026-07-17 weekly https://priors.science/q/amyloid-plaque-clearance-confirmed 2026-07-17 weekly https://priors.science/q/amyloid-targeting-antibodies-cause-amyloid-related-imaging-abnorm 2026-07-17 weekly https://priors.science/q/an-ifn-gene-expression-profile-score-is-associated-with-immune-ch 2026-07-17 weekly https://priors.science/q/anabolic-first-sequential-therapy-achieves-superior-bone-density 2026-07-17 weekly https://priors.science/q/androgen-receptor-splice-variant-7-ar-v7-expression-in-circulatin 2026-07-17 weekly https://priors.science/q/anifrolumab-reduces-cutaneous-lupus-disease-activity-clasi-score 2026-07-17 weekly https://priors.science/q/anifrolumab-reduces-sle-disease-activity-across-organ-domains-com 2026-07-17 weekly https://priors.science/q/antenatal-iron-supplementation-reduces-maternal-anaemia-at-term 2026-07-17 weekly https://priors.science/q/anthocyanin-rich-berries-improve-memory-in-older-adults 2026-07-17 weekly https://priors.science/q/anti-cgrp-antibodies-achieve-high-responder-rates-in-episodic-mig 2026-07-17 weekly https://priors.science/q/anti-cgrp-antibodies-achieve-medication-overuse-headache-remissio 2026-07-17 weekly https://priors.science/q/anti-cgrp-antibodies-have-low-discontinuation-due-to-adverse-even 2026-07-17 weekly https://priors.science/q/anti-cgrp-antibodies-increase-major-cardiovascular-event-risk 2026-07-17 weekly https://priors.science/q/anti-cgrp-antibodies-maintain-long-term-efficacy-in-chronic-migra 2026-07-17 weekly https://priors.science/q/anti-cgrp-antibodies-outperform-oral-preventives-in-treatment-res 2026-07-17 weekly https://priors.science/q/anti-cgrp-antibodies-prevent-chronic-cluster-headache 2026-07-17 weekly https://priors.science/q/anti-cgrp-antibodies-reduce-monthly-headache-days-in-chronic-migr 2026-07-17 weekly https://priors.science/q/anti-cgrp-antibodies-reduce-monthly-migraine-days-in-episodic-mig 2026-07-17 weekly https://priors.science/q/anti-cgrp-antibodies-treat-medication-overuse-headache-without-de 2026-07-17 weekly https://priors.science/q/anti-cgrp-monoclonal-antibodies-reduce-monthly-migraine-days-in-e 2026-07-17 weekly https://priors.science/q/anti-cgrp-monoclonal-antibodies-reduce-monthly-migraine-days-in-e-2 2026-07-17 weekly https://priors.science/q/anti-egfr-antibodies-benefit-left-sided-ras-wild-type-metastatic 2026-07-17 weekly https://priors.science/q/anti-il-5-agents-mepolizumab-benralizumab-reslizumab-significantl 2026-07-17 weekly https://priors.science/q/anti-il-5-therapy-enables-significant-oral-corticosteroid-dose-re 2026-07-17 weekly https://priors.science/q/anti-pd-1-monotherapy-pembrolizumab-or-nivolumab-improves-overall 2026-07-17 weekly https://priors.science/q/anti-pd-1-therapy-achieves-durable-objective-responses-in-msi-h-d 2026-07-17 weekly https://priors.science/q/anti-tnf-agents-infliximab-adalimumab-certolizumab-induce-clinica 2026-07-17 weekly https://priors.science/q/antibiotic-stewardship-programmes-reduce-consumption-without-incr 2026-07-17 weekly https://priors.science/q/anticoagulation-benefit-outweighs-bleeding-risk-in-af-on-dialysis 2026-07-17 weekly https://priors.science/q/anticoagulation-reduces-stroke-in-af-with-systolic-heart-failure 2026-07-17 weekly https://priors.science/q/antidepressant-effect-size-increases-with-baseline-depression-sev 2026-07-17 weekly https://priors.science/q/antidepressant-effect-size-is-small-versus-placebo-in-mild-to-mod 2026-07-17 weekly https://priors.science/q/antimicrobial-resistance-is-responsible-for-approximately-1-27-mi 2026-07-17 weekly https://priors.science/q/antimicrobial-stewardship-programmes-asps-in-hospital-settings-re 2026-07-17 weekly https://priors.science/q/antioxidant-supplements-do-not-reduce-all-cause-mortality 2026-07-17 weekly https://priors.science/q/antiretroviral-therapy-art-suppresses-hiv-viral-load-to-undetecta 2026-07-17 weekly https://priors.science/q/apixaban-reduces-stroke-in-subclinical-af-versus-aspirin 2026-07-17 weekly https://priors.science/q/apob-better-predicts-ascvd-risk-than-ldl-c 2026-07-17 weekly https://priors.science/q/apoe4-homozygote-aria-risk-elevated 2026-07-17 weekly https://priors.science/q/approved-anti-cgrp-antibodies-show-comparable-efficacy-in-episodi 2026-07-17 weekly https://priors.science/q/apremilast-achieves-pasi-75-in-about-30-percent-of-patients 2026-07-17 weekly https://priors.science/q/arbs-are-associated-with-lower-all-cause-mortality-than-acei-in-o 2026-07-17 weekly https://priors.science/q/arbs-have-significantly-lower-cough-and-angioedema-rates-than-ace 2026-07-17 weekly https://priors.science/q/arbs-reduce-kidney-disease-progression-in-diabetic-nephropathy 2026-07-17 weekly https://priors.science/q/aria-class-effect-confirmed 2026-07-17 weekly https://priors.science/q/arr-screening-detects-primary-aldosteronism-in-hypertension 2026-07-17 weekly https://priors.science/q/artificial-sweetener-consumption-is-associated-with-type-2-diabet 2026-07-17 weekly https://priors.science/q/artificial-sweetener-intake-is-associated-with-cardiovascular-dis 2026-07-17 weekly https://priors.science/q/aspartame-consumption-increases-cancer-risk-in-humans 2026-07-17 weekly https://priors.science/q/asthma-remission-defined-as-absence-of-exacerbations-elimination 2026-07-17 weekly https://priors.science/q/atezolizumab-bevacizumab-improves-overall-survival-over-sorafenib 2026-07-17 weekly https://priors.science/q/atezolizumab-monotherapy-is-non-inferior-to-chemotherapy-as-first 2026-07-17 weekly https://priors.science/q/atezolizumab-plus-bevacizumab-improves-overall-survival-and-progr 2026-07-17 weekly https://priors.science/q/atogepant-reduces-monthly-migraine-days-in-episodic-migraine 2026-07-17 weekly https://priors.science/q/atogepant-reduces-monthly-migraine-days-in-episodic-migraine-2 2026-07-17 weekly https://priors.science/q/atomoxetine-is-an-effective-non-stimulant-alternative-for-adhd-wi 2026-07-17 weekly https://priors.science/q/attr-cardiomyopathy-is-underdiagnosed-in-patients-with-heart-fail 2026-07-17 weekly https://priors.science/q/attr-therapy-and-tavr-combined-improve-survival-in-coexisting-aor 2026-07-17 weekly https://priors.science/q/atypical-antipsychotic-augmentation-improves-response-in-treatmen 2026-07-17 weekly https://priors.science/q/autologous-serum-drops-improve-severe-refractory-dry-eye 2026-07-17 weekly https://priors.science/q/autologous-serum-improves-dry-eye-in-sjogren-syndrome 2026-07-17 weekly https://priors.science/q/avatrombopag-increases-platelets-in-chronic-liver-disease-thrombo 2026-07-17 weekly https://priors.science/q/avelumab-maintenance-therapy-extends-overall-survival-compared-to 2026-07-17 weekly https://priors.science/q/avelumab-maintenance-therapy-prolongs-overall-survival-in-patient 2026-07-17 weekly https://priors.science/q/axicabtagene-ciloleucel-and-lisocabtagene-maraleucel-each-demonst 2026-07-17 weekly https://priors.science/q/axicabtagene-ciloleucel-axi-cel-produces-durable-complete-respons 2026-07-17 weekly https://priors.science/q/axicabtagene-ciloleucel-produces-high-complete-response-rates-and 2026-07-17 weekly https://priors.science/q/azithromycin-reduces-exacerbation-frequency-in-copd 2026-07-17 weekly https://priors.science/q/aztreonam-avibactam-is-active-against-metallo-beta-lactamase-ndm 2026-07-17 weekly https://priors.science/q/bacteriophage-therapy-has-demonstrated-proof-of-concept-in-compas 2026-07-17 weekly https://priors.science/q/bariatric-surgery-achieves-fibrosis-regression-in-70-of-nash-pati 2026-07-17 weekly https://priors.science/q/bariatric-surgery-is-superior-to-glp-1ra-for-nash-prevention 2026-07-17 weekly https://priors.science/q/bariatric-surgery-reduces-cardiovascular-events-versus-nonsurgica 2026-07-17 weekly https://priors.science/q/bariatric-surgery-reduces-major-adverse-liver-outcomes-versus-med 2026-07-17 weekly https://priors.science/q/bariatric-surgery-resolves-nash-in-84-of-patients-at-5-years 2026-07-17 weekly https://priors.science/q/bariatric-surgery-roux-en-y-gastric-bypass-or-sleeve-gastrectomy 2026-07-17 weekly https://priors.science/q/baricitinib-4-mg-does-not-achieve-statistically-significant-sri-4 2026-07-17 weekly https://priors.science/q/baricitinib-achieves-salt-20-in-38-of-severe-alopecia-areata 2026-07-17 weekly https://priors.science/q/baricitinib-is-effective-for-severe-alopecia-areata-in-adolescent 2026-07-17 weekly https://priors.science/q/baricitinib-reduces-skin-and-joint-inflammation-in-ssc 2026-07-17 weekly https://priors.science/q/baricitinib-retreatment-recaptures-response-in-most-aa-relapsers 2026-07-17 weekly https://priors.science/q/barzolvolimab-reduces-urticaria-activity-score-vs-placebo-in-anti 2026-07-17 weekly https://priors.science/q/basal-insulin-analogues-insulin-glargine-and-detemir-provide-equi 2026-07-17 weekly https://priors.science/q/basophil-activation-test-identifies-type-iib-autoimmune-endotype 2026-07-17 weekly https://priors.science/q/belimumab-added-to-standard-therapy-mycophenolate-or-cyclophospha 2026-07-17 weekly https://priors.science/q/belimumab-added-to-standard-therapy-reduces-overall-sle-disease-a 2026-07-17 weekly https://priors.science/q/bempedoic-acid-reduces-ldl-c-in-statin-intolerant-patients 2026-07-17 weekly https://priors.science/q/beta-blocker-therapy-reduces-all-cause-mortality-in-patients-with 2026-07-17 weekly https://priors.science/q/beta-blockers-are-less-effective-first-line-antihypertensive-agen 2026-07-17 weekly https://priors.science/q/beta-blockers-lack-mortality-benefit-in-acs-with-preserved-ejecti 2026-07-17 weekly https://priors.science/q/beta-blockers-reduce-mortality-in-acs-with-reduced-ejection-fract 2026-07-17 weekly https://priors.science/q/beta-carotene-supplements-increase-lung-cancer-risk-in-smokers 2026-07-17 weekly https://priors.science/q/bevacizumab-adds-limited-overall-survival-benefit-to-first-line-c 2026-07-17 weekly https://priors.science/q/bevacizumab-maintenance-extends-pfs-in-newly-diagnosed-advanced-o 2026-07-17 weekly https://priors.science/q/bevacizumab-plus-chemotherapy-extends-pfs-in-platinum-sensitive-r 2026-07-17 weekly https://priors.science/q/bevacizumab-plus-chemotherapy-improves-pfs-in-platinum-resistant 2026-07-17 weekly https://priors.science/q/beverage-electrolyte-content-raises-the-beverage-hydration-index 2026-07-17 weekly https://priors.science/q/bexotegrast-reduces-fvc-decline-in-ipf 2026-07-17 weekly https://priors.science/q/bictegravir-tenofovir-alafenamide-emtricitabine-b-f-taf-provides 2026-07-17 weekly https://priors.science/q/bilateral-lung-transplant-provides-superior-outcomes-versus-singl 2026-07-17 weekly https://priors.science/q/bimekizumab-achieves-acr50-superior-to-placebo-in-biologic-naive 2026-07-17 weekly https://priors.science/q/bimekizumab-achieves-superior-pasi-90-versus-secukinumab-in-plaqu 2026-07-17 weekly https://priors.science/q/biologic-response-in-axial-psoriatic-arthritis-is-lower-than-in-a 2026-07-17 weekly https://priors.science/q/biologic-step-down-and-discontinuation-in-severe-asthma-patients 2026-07-17 weekly https://priors.science/q/biologics-lower-cardiovascular-risk-versus-oral-systemics-in-psor 2026-07-17 weekly https://priors.science/q/bispecific-antibodies-increase-serious-infection-risk-in-haematol 2026-07-17 weekly https://priors.science/q/bisphosphonate-fracture-benefits-outweigh-atypical-femoral-fractu 2026-07-17 weekly https://priors.science/q/bisphosphonate-use-after-denosumab-prevents-rebound-bone-loss 2026-07-17 weekly https://priors.science/q/bisphosphonates-reduce-fracture-risk-in-glucocorticoid-induced-os 2026-07-17 weekly https://priors.science/q/bisphosphonates-reduce-hip-fracture-risk-in-postmenopausal-osteop 2026-07-17 weekly https://priors.science/q/bisphosphonates-reduce-vertebral-fracture-risk-in-postmenopausal 2026-07-17 weekly https://priors.science/q/blood-based-tumour-mutational-burden-btmb-correlates-imperfectly 2026-07-17 weekly https://priors.science/q/blood-eosinophil-count-and-feno-values-fluctuate-on-inhaled-corti 2026-07-17 weekly https://priors.science/q/blood-eosinophil-count-of-300-cells-l-or-greater-is-the-primary-p 2026-07-17 weekly https://priors.science/q/blood-eosinophils-predict-ics-exacerbation-benefit-in-copd 2026-07-17 weekly https://priors.science/q/blood-pressure-lowering-reduces-mortality-in-ckd-patients 2026-07-17 weekly https://priors.science/q/bosentan-reduces-new-digital-ulcer-formation-in-ssc 2026-07-17 weekly https://priors.science/q/brain-penetrant-btk-inhibitors-reduce-6-month-confirmed-disabilit 2026-07-17 weekly https://priors.science/q/brca-mutation-status-predicts-parp-inhibitor-benefit-in-ovarian-c 2026-07-17 weekly https://priors.science/q/brexucabtagene-autoleucel-produces-high-complete-remission-rates 2026-07-17 weekly https://priors.science/q/brexucabtagene-autoleucel-produces-high-overall-response-rates-an 2026-07-17 weekly https://priors.science/q/broadly-neutralising-antibodies-bnabs-in-combination-can-suppress 2026-07-17 weekly https://priors.science/q/btk-inhibition-achieves-meaningful-response-within-2-weeks-in-csu 2026-07-17 weekly https://priors.science/q/btk-inhibition-modulates-microglial-activation-in-neuroinflammati 2026-07-17 weekly https://priors.science/q/btk-inhibitor-treatment-reduces-serum-neurofilament-light-chain-l 2026-07-17 weekly https://priors.science/q/btk-inhibitors-are-superior-to-teriflunomide-for-annualized-relap 2026-07-17 weekly https://priors.science/q/btk-inhibitors-developed-for-multiple-sclerosis-are-not-associate 2026-07-17 weekly https://priors.science/q/btk-inhibitors-reduce-6-month-confirmed-disability-worsening-in-r 2026-07-17 weekly https://priors.science/q/btk-inhibitors-reduce-gadolinium-enhancing-t1-lesions-in-relapsin 2026-07-17 weekly https://priors.science/q/btk-inhibitors-reduce-the-volume-of-slowly-expanding-lesions-an-m 2026-07-17 weekly https://priors.science/q/btk-inhibitors-used-in-multiple-sclerosis-clinical-trials-are-ass 2026-07-17 weekly https://priors.science/q/btk-inhibitors-used-in-multiple-sclerosis-preserve-circulating-b 2026-07-17 weekly https://priors.science/q/btk-is-expressed-in-microglia-and-macrophages-within-active-and-c 2026-07-17 weekly https://priors.science/q/buprenorphine-is-non-inferior-to-full-agonist-opioids-for-chronic 2026-07-17 weekly https://priors.science/q/cabg-reduces-long-term-mortality-versus-pci-in-multivessel-acs 2026-07-17 weekly https://priors.science/q/cabozantinib-prolongs-overall-survival-in-previously-treated-adva 2026-07-17 weekly https://priors.science/q/caffeine-before-exercise-impairs-subsequent-sleep 2026-07-17 weekly https://priors.science/q/caffeine-improves-alertness-and-reaction-time 2026-07-17 weekly https://priors.science/q/caffeine-improves-endurance-exercise-performance 2026-07-17 weekly https://priors.science/q/caffeine-improves-muscular-strength-and-power-output 2026-07-17 weekly https://priors.science/q/caffeine-improves-sprint-and-high-intensity-performance 2026-07-17 weekly https://priors.science/q/caffeine-mouth-rinse-improves-exercise-performance 2026-07-17 weekly https://priors.science/q/caffeine-reduces-perceived-exertion-during-endurance-exercise 2026-07-17 weekly https://priors.science/q/caffeine-restores-cognitive-performance-during-sleep-deprivation 2026-07-17 weekly https://priors.science/q/caffeine-s-ergogenic-effect-follows-a-dose-response-relationship 2026-07-17 weekly https://priors.science/q/calcimimetics-reduce-parathyroid-hormone-in-secondary-hyperparath 2026-07-17 weekly https://priors.science/q/canagliflozin-is-associated-with-increased-risk-of-lower-limb-amp 2026-07-17 weekly https://priors.science/q/canagliflozin-reduces-the-composite-of-sustained-doubling-of-seru 2026-07-17 weekly https://priors.science/q/cangrelor-improves-outcomes-vs-oral-p2y12-in-cardiogenic-shock-pc 2026-07-17 weekly https://priors.science/q/cangrelor-reduces-stent-thrombosis-vs-clopidogrel-loading-during 2026-07-17 weekly https://priors.science/q/cannabidiol-reduces-drop-seizures-in-lennox-gastaut-syndrome 2026-07-17 weekly https://priors.science/q/capivasertib-plus-fulvestrant-extends-progression-free-survival-i 2026-07-17 weekly https://priors.science/q/carbapenem-resistant-enterobacterales-cre-carbapenem-resistant-ac 2026-07-17 weekly https://priors.science/q/carbapenemase-producing-organisms-cpo-including-kpc-oxa-48-ndm-an 2026-07-17 weekly https://priors.science/q/carboplatin-and-paclitaxel-remain-standard-first-line-therapy-in 2026-07-17 weekly https://priors.science/q/cardiac-resynchronisation-therapy-reduces-all-cause-mortality-in 2026-07-17 weekly https://priors.science/q/cardiotoxicity-is-a-class-adverse-effect-of-her2-targeted-therapy 2026-07-17 weekly https://priors.science/q/cardiovascular-benefit-from-glp-1-receptor-agonists-is-a-class-ef 2026-07-17 weekly https://priors.science/q/catheter-ablation-improves-lv-function-in-af-with-hfref 2026-07-17 weekly https://priors.science/q/catheter-ablation-reduces-af-recurrence-versus-antiarrhythmic-dru 2026-07-17 weekly https://priors.science/q/caz-avi-achieves-clinical-cure-in-most-serious-cre-infections 2026-07-17 weekly https://priors.science/q/caz-avi-plus-aztreonam-is-effective-against-mbl-producing-organis 2026-07-17 weekly https://priors.science/q/caz-avi-reduces-mortality-in-kpc-cre-infections-versus-older-agen 2026-07-17 weekly https://priors.science/q/ccb-and-ace-inhibitor-reduce-cardiovascular-events-equivalently 2026-07-17 weekly https://priors.science/q/cd19-antigen-loss-or-downregulation-is-the-primary-mechanism-of-r 2026-07-17 weekly https://priors.science/q/cdk4-6-inhibitors-plus-endocrine-therapy-extend-survival-in-advan 2026-07-17 weekly https://priors.science/q/cefiderocol-a-siderophore-cephalosporin-is-active-against-most-ca 2026-07-17 weekly https://priors.science/q/cefiderocol-achieves-high-cure-rates-in-non-acinetobacter-resista 2026-07-17 weekly https://priors.science/q/cefiderocol-has-excess-mortality-risk-in-acinetobacter-baumannii 2026-07-17 weekly https://priors.science/q/ceftazidime-avibactam-is-effective-against-kpc-and-oxa-48-produci 2026-07-17 weekly https://priors.science/q/ceftolozane-tazobactam-and-imipenem-cilastatin-relebactam-are-act 2026-07-17 weekly https://priors.science/q/ceftolozane-tazobactam-is-effective-for-dtr-pseudomonas-aeruginos 2026-07-17 weekly https://priors.science/q/ceftolozane-tazobactam-resistance-emergence-exceeds-caz-avi-durin 2026-07-17 weekly https://priors.science/q/cftr-modulator-therapy-particularly-eti-reduces-the-incidence-and 2026-07-17 weekly https://priors.science/q/cgrp-is-elevated-during-spontaneous-migraine-attacks 2026-07-17 weekly https://priors.science/q/cha2ds2-va-performs-comparably-to-cha2ds2-vasc-for-stroke-predict 2026-07-17 weekly https://priors.science/q/cha2ds2-vasc-predicts-stroke-in-non-valvular-af 2026-07-17 weekly https://priors.science/q/cholinesterase-inhibitors-provide-modest-symptomatic-cognitive-be 2026-07-17 weekly https://priors.science/q/cilofexor-reduces-liver-fat-content-in-nash-without-cirrhosis 2026-07-17 weekly https://priors.science/q/ciltacabtagene-autoleucel-cilta-cel-significantly-improves-progre 2026-07-17 weekly https://priors.science/q/circadian-misalignment-impairs-glucose-tolerance 2026-07-17 weekly https://priors.science/q/clonal-neoantigen-burden-reflecting-tumour-specific-mutations-pre 2026-07-17 weekly https://priors.science/q/clopidogrel-aspirin-reduces-stroke-recurrence-vs-aspirin-after-ti 2026-07-17 weekly https://priors.science/q/clopidogrel-is-noninferior-to-ticagrelor-in-elderly-acs-patients 2026-07-17 weekly https://priors.science/q/closed-loop-automated-insulin-delivery-artificial-pancreas-system 2026-07-17 weekly https://priors.science/q/cns-penetrant-btk-inhibition-preferentially-targets-the-smoulderi 2026-07-17 weekly https://priors.science/q/cns-penetrant-btk-inhibition-reduces-neurodegeneration-and-axonal 2026-07-17 weekly https://priors.science/q/cns-penetrant-btk-inhibitors-achieve-bioactive-concentrations-in 2026-07-17 weekly https://priors.science/q/cocoa-flavanols-improve-endothelial-function 2026-07-17 weekly https://priors.science/q/cocoa-flavanols-modestly-reduce-blood-pressure 2026-07-17 weekly https://priors.science/q/cognitive-behavioural-therapy-reduces-migraine-burden 2026-07-17 weekly https://priors.science/q/cognitive-impairment-in-long-covid-brain-fog-is-associated-with-m 2026-07-17 weekly https://priors.science/q/colchicine-reduces-mace-after-myocardial-infarction 2026-07-17 weekly https://priors.science/q/colchicine-reduces-mace-after-myocardial-infarction-2 2026-07-17 weekly https://priors.science/q/colchicine-reduces-mace-in-chronic-coronary-disease 2026-07-17 weekly https://priors.science/q/colistin-based-combination-regimens-for-carbapenem-resistant-orga 2026-07-17 weekly https://priors.science/q/combination-era-and-pde5i-improves-survival-in-ssc-pah 2026-07-17 weekly https://priors.science/q/combination-low-dose-aspirin-and-heparin-lmwh-or-ufh-reduces-preg 2026-07-17 weekly https://priors.science/q/combination-therapy-ceftazidime-avibactam-plus-aztreonam-for-ndm 2026-07-17 weekly https://priors.science/q/combination-therapy-with-anti-tnf-agents-plus-an-immunomodulator 2026-07-17 weekly https://priors.science/q/combinations-of-ici-with-vegfr-targeted-therapy-pembrolizumab-plu 2026-07-17 weekly https://priors.science/q/combined-calcium-and-vitamin-d-reduces-fracture-risk-in-older-adu 2026-07-17 weekly https://priors.science/q/combining-duloxetine-and-pregabalin-improves-neuropathic-pain-ove 2026-07-17 weekly https://priors.science/q/combining-multiple-predictive-biomarkers-e-g-pd-l1-plus-tmb-or-pd 2026-07-17 weekly https://priors.science/q/combining-parp-inhibitors-with-next-generation-ar-pathway-inhibit 2026-07-17 weekly https://priors.science/q/complete-revascularization-reduces-mace-versus-incomplete-in-mult 2026-07-17 weekly https://priors.science/q/composite-biomarker-profiles-combining-blood-eosinophils-feno-tot 2026-07-17 weekly https://priors.science/q/compound-alk-mutations-underlie-acquired-lorlatinib-resistance 2026-07-17 weekly https://priors.science/q/continuous-glucose-monitoring-produces-clinically-modest-but-stat 2026-07-17 weekly https://priors.science/q/continuous-subcutaneous-apomorphine-or-levodopa-carbidopa-intesti 2026-07-17 weekly https://priors.science/q/correcting-metabolic-acidosis-with-bicarbonate-preserves-muscle-m 2026-07-17 weekly https://priors.science/q/correcting-vitamin-d-deficiency-reduces-mortality-in-deficient-ad 2026-07-17 weekly https://priors.science/q/cortical-spreading-depression-underlies-the-migraine-aura 2026-07-17 weekly https://priors.science/q/corticosteroids-lack-rct-evidence-for-benefit-in-ipf-exacerbation 2026-07-17 weekly https://priors.science/q/covid-19-vaccination-reduces-the-risk-of-developing-long-covid-fo 2026-07-17 weekly https://priors.science/q/cpap-therapy-improves-glycemic-control-in-apnea 2026-07-17 weekly https://priors.science/q/cre-bacteraemia-carries-30-to-45-percent-30-day-mortality 2026-07-17 weekly https://priors.science/q/creatine-attenuates-cognitive-decline-from-sleep-deprivation 2026-07-17 weekly https://priors.science/q/creatine-enhances-muscle-gains-in-older-adults 2026-07-17 weekly https://priors.science/q/creatine-improves-high-intensity-and-repeated-sprint-performance 2026-07-17 weekly https://priors.science/q/creatine-improves-muscle-function-in-muscular-dystrophy 2026-07-17 weekly https://priors.science/q/creatine-increases-lean-body-mass-during-resistance-training 2026-07-17 weekly https://priors.science/q/creatine-increases-muscle-strength-during-resistance-training 2026-07-17 weekly https://priors.science/q/creatine-supplementation-impairs-kidney-function-in-healthy-adult 2026-07-17 weekly https://priors.science/q/creatine-supplementation-improves-cognitive-performance-in-health 2026-07-17 weekly https://priors.science/q/creatine-supplementation-increases-muscle-cramping-and-dehydratio 2026-07-17 weekly https://priors.science/q/creatine-supplementation-reduces-depression-symptoms 2026-07-17 weekly https://priors.science/q/creatine-with-resistance-training-improves-bone-health-in-older-a 2026-07-17 weekly https://priors.science/q/crizotinib-achieves-meaningful-orr-in-ros1-nsclc 2026-07-17 weekly https://priors.science/q/crizotinib-is-active-in-alk-inflammatory-myofibroblastic-tumor 2026-07-17 weekly https://priors.science/q/crt-with-defibrillator-crt-d-and-crt-with-pacemaker-crt-p-do-not 2026-07-17 weekly https://priors.science/q/csu-causes-substantial-quality-of-life-impairment-comparable-to-s 2026-07-17 weekly https://priors.science/q/csu-persists-beyond-5-years-in-majority-of-patients-with-moderate 2026-07-17 weekly https://priors.science/q/ctla-4-blockade-depletes-intratumoral-regulatory-t-cells-to-enhan 2026-07-17 weekly https://priors.science/q/ctla-4-inhibitors-cause-substantially-higher-grade-3-or-greater-i 2026-07-17 weekly https://priors.science/q/current-aav-mediated-gene-therapies-for-lgmd-subtypes-have-not-de 2026-07-17 weekly https://priors.science/q/current-evidence-does-not-support-routine-use-of-anticoagulation 2026-07-17 weekly https://priors.science/q/cyclophosphamide-improves-fvc-in-early-ssc-ild 2026-07-17 weekly https://priors.science/q/cyclosporin-achieves-faster-easi-response-than-methotrexate-in-at 2026-07-17 weekly https://priors.science/q/cyclosporine-0-05-increases-schirmer-scores-in-dry-eye-disease 2026-07-17 weekly https://priors.science/q/cyclosporine-achieves-clinically-meaningful-uas7-reduction-in-ant 2026-07-17 weekly https://priors.science/q/cyclosporine-causes-clinically-significant-nephrotoxicity-requiri 2026-07-17 weekly https://priors.science/q/cyp1a2-genotype-moderates-caffeine-s-ergogenic-effect 2026-07-17 weekly https://priors.science/q/cyp2c19-loss-of-function-alleles-increase-mace-risk-with-clopidog 2026-07-17 weekly https://priors.science/q/cytokine-release-syndrome-crs-and-immune-effector-cell-associated 2026-07-17 weekly https://priors.science/q/cytokine-release-syndrome-with-bispecific-antibodies-is-predomina 2026-07-17 weekly https://priors.science/q/dabrafenib-plus-trametinib-braf-mek-inhibitor-combination-achieve 2026-07-17 weekly https://priors.science/q/daily-oral-tenofovir-based-pre-exposure-prophylaxis-prep-reduces 2026-07-17 weekly https://priors.science/q/dalbavancin-achieves-high-cure-rates-in-acute-bacterial-skin-infe 2026-07-17 weekly https://priors.science/q/dalbavancin-is-effective-for-osteomyelitis-and-deep-seated-bone-i 2026-07-17 weekly https://priors.science/q/dapagliflozin-reduces-the-risk-of-sustained-50-egfr-decline-end-s 2026-07-17 weekly https://priors.science/q/dapt-benefit-in-tia-and-minor-stroke-is-confined-to-the-first-21 2026-07-17 weekly https://priors.science/q/dapt-de-escalation-to-clopidogrel-is-non-inferior-for-mace-post-a 2026-07-17 weekly https://priors.science/q/daptomycin-and-linezolid-remain-effective-first-line-options-for 2026-07-17 weekly https://priors.science/q/daratumumab-plus-vcd-improves-haematologic-and-organ-response-in 2026-07-17 weekly https://priors.science/q/dash-diet-plus-sodium-restriction-provides-additive-blood-pressur 2026-07-17 weekly https://priors.science/q/de-escalation-to-clopidogrel-reduces-bleeding-vs-potent-p2y12-con 2026-07-17 weekly https://priors.science/q/deep-brain-stimulation-of-the-subthalamic-nucleus-or-globus-palli 2026-07-17 weekly https://priors.science/q/delandistrogene-moxeparvovec-produces-a-clinically-meaningful-imp 2026-07-17 weekly https://priors.science/q/delandistrogene-moxeparvovec-produces-measurable-micro-dystrophin 2026-07-17 weekly https://priors.science/q/denosumab-discontinuation-causes-rebound-vertebral-fracture-risk 2026-07-17 weekly https://priors.science/q/denosumab-increases-bone-mineral-density-more-than-bisphosphonate 2026-07-17 weekly https://priors.science/q/denosumab-rankl-inhibitor-delays-skeletal-related-events-sres-in 2026-07-17 weekly https://priors.science/q/denosumab-reduces-fracture-risk-similarly-to-bisphosphonates 2026-07-17 weekly https://priors.science/q/deucravacitinib-achieves-superior-pasi-75-versus-apremilast-in-pl 2026-07-17 weekly https://priors.science/q/deuruxolitinib-achieves-salt-20-in-41-of-alopecia-areata-patients 2026-07-17 weekly https://priors.science/q/development-of-immune-related-adverse-events-is-independently-ass 2026-07-17 weekly https://priors.science/q/dietary-acid-reduction-with-protein-restriction-slows-ckd-progres 2026-07-17 weekly https://priors.science/q/dietary-fibre-improves-chronic-constipation-and-stool-frequency 2026-07-17 weekly https://priors.science/q/dietary-fibre-intake-lowers-systemic-inflammation 2026-07-17 weekly https://priors.science/q/dietary-fibre-supplementation-lowers-blood-pressure 2026-07-17 weekly https://priors.science/q/dietary-polyphenol-intake-reduces-colorectal-cancer-risk 2026-07-17 weekly https://priors.science/q/dietary-sugar-restriction-reduces-liver-fat-in-nafld 2026-07-17 weekly https://priors.science/q/different-pd-l1-assay-clones-and-scoring-methods-are-not-intercha 2026-07-17 weekly https://priors.science/q/diquafosol-improves-tear-film-break-up-time-in-dry-eye 2026-07-17 weekly https://priors.science/q/disease-modifying-therapy-status 2026-07-17 weekly https://priors.science/q/dmmr-msi-h-endometrial-carcinoma-shows-robust-immune-checkpoint-i 2026-07-17 weekly https://priors.science/q/doacs-reduce-intracranial-haemorrhage-versus-warfarin-in-af 2026-07-17 weekly https://priors.science/q/doacs-reduce-net-adverse-events-versus-vka-in-af-with-ckd 2026-07-17 weekly https://priors.science/q/doacs-reduce-stroke-risk-versus-warfarin-in-non-valvular-af 2026-07-17 weekly https://priors.science/q/dolutegravir-based-regimens-are-superior-or-non-inferior-to-other 2026-07-17 weekly https://priors.science/q/donanemab-slows-ad-decline 2026-07-17 weekly https://priors.science/q/donanemab-slows-clinical-decline-in-early-symptomatic-alzheimer-s 2026-07-17 weekly https://priors.science/q/dose-dense-mvac-is-superior-to-gemcitabine-cisplatin-as-neoadjuva 2026-07-17 weekly https://priors.science/q/dose-dense-paclitaxel-improves-outcomes-versus-standard-schedulin 2026-07-17 weekly https://priors.science/q/dual-acei-plus-arb-therapy-increases-risk-of-hyperkalemia-and-acu 2026-07-17 weekly https://priors.science/q/dual-raas-blockade-increases-adverse-renal-outcomes-in-ckd 2026-07-17 weekly https://priors.science/q/dual-raas-blockade-increases-hyperkalaemia-and-acute-kidney-injur 2026-07-17 weekly https://priors.science/q/duloxetine-reduces-pain-and-disability-in-diabetic-neuropathic-pa 2026-07-17 weekly https://priors.science/q/duloxetine-reduces-pain-in-fibromyalgia-and-diabetic-peripheral-n 2026-07-17 weekly https://priors.science/q/dupilumab-achieves-easi-75-in-moderate-to-severe-atopic-dermatiti 2026-07-17 weekly https://priors.science/q/dupilumab-achieves-oral-corticosteroid-elimination-or-significant 2026-07-17 weekly https://priors.science/q/dupilumab-has-limited-efficacy-in-unselected-alopecia-areata 2026-07-17 weekly https://priors.science/q/dupilumab-has-superior-drug-survival-versus-conventional-systemic 2026-07-17 weekly https://priors.science/q/dupilumab-is-effective-in-atopic-dermatitis-with-asthma-comorbidi 2026-07-17 weekly https://priors.science/q/dupilumab-reduces-angioedema-activity-score-in-csu 2026-07-17 weekly https://priors.science/q/dupilumab-reduces-exacerbation-rates-and-improves-lung-function-i 2026-07-17 weekly https://priors.science/q/dupilumab-reduces-exacerbations-in-eosinophilic-copd 2026-07-17 weekly https://priors.science/q/dupilumab-reduces-pruritus-nrs-in-atopic-dermatitis 2026-07-17 weekly https://priors.science/q/dupilumab-reduces-urticaria-activity-score-vs-placebo-in-antihist 2026-07-17 weekly https://priors.science/q/durvalumab-added-to-tace-extends-progression-free-survival-in-hcc 2026-07-17 weekly https://priors.science/q/durvalumab-tremelimumab-improves-overall-survival-over-sorafenib 2026-07-17 weekly https://priors.science/q/dynamic-kl-6-change-independently-predicts-ipf-acute-exacerbation 2026-07-17 weekly https://priors.science/q/earlier-initiation-of-tafamidis-is-associated-with-superior-survi 2026-07-17 weekly https://priors.science/q/earlier-initiation-of-tofersen-confers-greater-functional-benefit 2026-07-17 weekly https://priors.science/q/earlier-pcsk9-inhibitor-start-post-acs-reduces-subsequent-mace 2026-07-17 weekly https://priors.science/q/early-aggressive-antibiotic-eradication-of-pseudomonas-aeruginosa 2026-07-17 weekly https://priors.science/q/early-anticoagulation-after-af-stroke-is-safe 2026-07-17 weekly https://priors.science/q/early-circulating-tumour-dna-clearance-during-immune-checkpoint-i 2026-07-17 weekly https://priors.science/q/early-combination-therapy-with-two-or-more-glucose-lowering-agent 2026-07-17 weekly https://priors.science/q/early-ezetimibe-after-mi-reduces-recurrent-cardiovascular-events 2026-07-17 weekly https://priors.science/q/early-in-hospital-sacubitril-valsartan-initiation-improves-post-h 2026-07-17 weekly https://priors.science/q/early-initiation-of-belimumab-disease-duration-2-years-no-prior-o 2026-07-17 weekly https://priors.science/q/early-nirmatrelvir-ritonavir-treatment-of-acute-covid-19-reduces 2026-07-17 weekly https://priors.science/q/early-rhythm-control-benefit-diminishes-in-elderly-af-patients 2026-07-17 weekly https://priors.science/q/early-rhythm-control-reduces-cardiovascular-events-in-af 2026-07-17 weekly https://priors.science/q/early-time-restricted-eating-improves-insulin-sensitivity-indepen 2026-07-17 weekly https://priors.science/q/early-time-restricted-eating-lowers-blood-pressure 2026-07-17 weekly https://priors.science/q/early-top-down-anti-tnf-therapy-produces-superior-long-term-mucos 2026-07-17 weekly https://priors.science/q/edaravone-slows-functional-decline-in-motor-neurone-disease 2026-07-17 weekly https://priors.science/q/effective-treatment-improves-psychological-outcomes-in-alopecia-a 2026-07-17 weekly https://priors.science/q/effects-exceed-clinical-mid 2026-07-17 weekly https://priors.science/q/electroconvulsive-therapy-produces-remission-in-treatment-resista 2026-07-17 weekly https://priors.science/q/electrolyte-deficiency-causes-exercise-associated-muscle-cramps 2026-07-17 weekly https://priors.science/q/electrolyte-drinks-reduce-muscle-cramp-susceptibility-more-than-w 2026-07-17 weekly https://priors.science/q/elevated-fgf-23-predicts-cardiovascular-mortality-in-ckd-patients 2026-07-17 weekly https://priors.science/q/elevated-hscrp-predicts-mace-independently-of-ldl-in-statin-treat 2026-07-17 weekly https://priors.science/q/elevated-lp-a-independently-predicts-major-cardiovascular-events 2026-07-17 weekly https://priors.science/q/elexacaftor-tezacaftor-ivacaftor-eti-triple-therapy-produces-larg 2026-07-17 weekly https://priors.science/q/elexacaftor-tezacaftor-ivacaftor-substantially-reduces-the-freque 2026-07-17 weekly https://priors.science/q/elranatamab-produces-durable-responses-in-relapsed-refractory-mul 2026-07-17 weekly https://priors.science/q/eltrombopag-added-to-immunosuppressive-therapy-improves-response 2026-07-17 weekly https://priors.science/q/eltrombopag-increases-platelet-counts-and-reduces-bleeding-in-chr 2026-07-17 weekly https://priors.science/q/eltrombopag-increases-platelets-in-hepatitis-c-thrombocytopenia-t 2026-07-17 weekly https://priors.science/q/eltrombopag-produces-haematologic-responses-in-refractory-severe 2026-07-17 weekly https://priors.science/q/eml4-alk-variant-3-associates-with-higher-resistance-mutation-ris 2026-07-17 weekly https://priors.science/q/empagliflozin-reduces-cardiovascular-death-in-t2d-patients-with-e 2026-07-17 weekly https://priors.science/q/empagliflozin-reduces-cardiovascular-mortality-in-people-with-typ 2026-07-17 weekly https://priors.science/q/empagliflozin-reduces-liver-fat-content-in-t2d-patients-with-nafl 2026-07-17 weekly https://priors.science/q/encorafenib-plus-cetuximab-improves-survival-in-braf-v600e-colore 2026-07-17 weekly https://priors.science/q/enfortumab-vedotin-combined-with-pembrolizumab-is-superior-to-pla 2026-07-17 weekly https://priors.science/q/enfortumab-vedotin-monotherapy-improves-overall-survival-compared 2026-07-17 weekly https://priors.science/q/enfortumab-vedotin-plus-pembrolizumab-improves-overall-survival-v 2026-07-17 weekly https://priors.science/q/ensifentrine-reduces-exacerbations-as-add-on-copd-therapy 2026-07-17 weekly https://priors.science/q/enzalutamide-apalutamide-and-darolutamide-each-demonstrate-signif 2026-07-17 weekly https://priors.science/q/enzalutamide-significantly-improves-metastasis-free-survival-in-h 2026-07-17 weekly https://priors.science/q/enzalutamide-significantly-improves-overall-survival-compared-to 2026-07-17 weekly https://priors.science/q/epcoritamab-monotherapy-produces-durable-responses-in-relapsed-la 2026-07-17 weekly https://priors.science/q/eplontersen-reduces-serum-ttr-and-improves-cardiac-parameters-in 2026-07-17 weekly https://priors.science/q/eptinezumab-given-during-attack-achieves-rapid-pain-freedom 2026-07-17 weekly https://priors.science/q/era-plus-pde5-inhibitor-outperforms-monotherapy-in-pah 2026-07-17 weekly https://priors.science/q/erdafitinib-improves-overall-survival-compared-with-chemotherapy 2026-07-17 weekly https://priors.science/q/erenumab-is-associated-with-blood-pressure-increases 2026-07-17 weekly https://priors.science/q/erenumab-shows-superior-tolerability-versus-topiramate-in-migrain 2026-07-17 weekly https://priors.science/q/erythritol-intake-is-associated-with-cardiovascular-events 2026-07-17 weekly https://priors.science/q/erythropoiesis-stimulating-agents-increase-haemoglobin-in-ckd 2026-07-17 weekly https://priors.science/q/escitalopram-and-sertraline-have-the-best-efficacy-and-acceptabil 2026-07-17 weekly https://priors.science/q/eti-triple-therapy-improves-cf-related-liver-disease-markers-and 2026-07-17 weekly https://priors.science/q/eti-triple-therapy-significantly-reduces-sweat-chloride-concentra 2026-07-17 weekly https://priors.science/q/even-protein-distribution-across-meals-augments-muscle-accretion 2026-07-17 weekly https://priors.science/q/exercise-based-cardiac-rehabilitation-reduces-cardiovascular-mort 2026-07-17 weekly https://priors.science/q/exercise-based-cardiac-rehabilitation-reduces-reinfarction-risk-p 2026-07-17 weekly https://priors.science/q/exercise-interventions-reduce-fall-related-fracture-risk-in-older 2026-07-17 weekly https://priors.science/q/exercise-reduces-fall-rate-by-23-in-community-dwelling-older-adul 2026-07-17 weekly https://priors.science/q/experimental-sleep-restriction-reduces-insulin-sensitivity 2026-07-17 weekly https://priors.science/q/extended-dapt-reduces-mi-but-increases-non-cardiac-mortality-vs-1 2026-07-17 weekly https://priors.science/q/extended-spectrum-beta-lactamase-esbl-producing-enterobacterales 2026-07-17 weekly https://priors.science/q/ezetimibe-added-to-statin-reduces-major-cardiovascular-events 2026-07-17 weekly https://priors.science/q/ezetimibe-added-to-statins-reduces-cardiovascular-events-post-acs 2026-07-17 weekly https://priors.science/q/fast-score-identifies-high-risk-nash-patients-with-auroc-above-0 2026-07-17 weekly https://priors.science/q/fda-rejected-obeticholic-acid-for-nash-due-to-insufficient-benefi 2026-07-17 weekly https://priors.science/q/febuxostat-does-not-significantly-slow-ckd-progression-in-stage-3 2026-07-17 weekly https://priors.science/q/fecal-calprotectin-is-a-reliable-non-invasive-biomarker-for-predi 2026-07-17 weekly https://priors.science/q/female-patients-derive-greater-benefit-from-sacubitril-valsartan 2026-07-17 weekly https://priors.science/q/female-sex-independently-increases-stroke-risk-in-af 2026-07-17 weekly https://priors.science/q/female-sex-pre-existing-autoimmune-conditions-and-higher-acute-co 2026-07-17 weekly https://priors.science/q/fenfluramine-reduces-convulsive-seizures-in-dravet-syndrome 2026-07-17 weekly https://priors.science/q/fenofibrate-reduces-the-risk-of-progression-of-diabetic-retinopat 2026-07-17 weekly https://priors.science/q/fermentable-fibre-increases-short-chain-fatty-acid-producing-gut 2026-07-17 weekly https://priors.science/q/ffr-guided-pci-and-cabg-have-similar-outcomes-in-multivessel-nste 2026-07-17 weekly https://priors.science/q/fgfr2-3-genomic-alterations-reliably-predict-clinical-benefit-fro 2026-07-17 weekly https://priors.science/q/fib-4-below-1-3-effectively-rules-out-advanced-fibrosis-in-nafld 2026-07-17 weekly https://priors.science/q/fib-4-greater-than-2-67-predicts-4-fold-higher-cardiovascular-eve 2026-07-17 weekly https://priors.science/q/fib-4-index-is-validated-for-detecting-advanced-fibrosis-in-nafld 2026-07-17 weekly https://priors.science/q/fib-4-index-predicts-cardiovascular-events-in-nafld-patients 2026-07-17 weekly https://priors.science/q/fibrosis-stage-independently-predicts-all-cause-mortality-in-nafl 2026-07-17 weekly https://priors.science/q/finerenone-combined-with-sglt2-inhibitors-reduces-ckd-risk 2026-07-17 weekly https://priors.science/q/finerenone-efficacy-extends-to-non-diabetic-ckd-patients 2026-07-17 weekly https://priors.science/q/finerenone-reduces-cardiovascular-and-renal-events-in-ckd-with-t2 2026-07-17 weekly https://priors.science/q/finerenone-reduces-cardiovascular-events-in-diabetic-ckd 2026-07-17 weekly https://priors.science/q/finerenone-reduces-heart-failure-hospitalizations-in-hfmref-and-h 2026-07-17 weekly https://priors.science/q/finerenone-reduces-kidney-disease-progression-in-diabetic-ckd 2026-07-17 weekly https://priors.science/q/finerenone-reduces-kidney-outcomes-beyond-raas-blockade-in-ckd 2026-07-17 weekly https://priors.science/q/finerenone-reduces-the-total-burden-of-heart-failure-hospitalisat 2026-07-17 weekly https://priors.science/q/finerenone-reduces-urine-albumin-to-creatinine-ratio-in-diabetic 2026-07-17 weekly https://priors.science/q/fixed-ratio-combinations-of-basal-insulin-and-glp-1-receptor-agon 2026-07-17 weekly https://priors.science/q/flash-glucose-monitoring-intermittently-scanned-cgm-reduces-hba1c 2026-07-17 weekly https://priors.science/q/fondaparinux-reduces-major-bleeding-versus-enoxaparin-in-nste-acs 2026-07-17 weekly https://priors.science/q/four-strata-compera-outperforms-three-strata-risk-scoring-in-pah 2026-07-17 weekly https://priors.science/q/fractional-exhaled-nitric-oxide-feno-of-25-ppb-or-greater-identif 2026-07-17 weekly https://priors.science/q/fracture-liaison-services-reduce-secondary-fracture-incidence 2026-07-17 weekly https://priors.science/q/frax-fracture-risk-tool-improves-treatment-targeting-in-osteoporo 2026-07-17 weekly https://priors.science/q/fructose-consumption-promotes-hepatic-fat-accumulation 2026-07-17 weekly https://priors.science/q/fructose-intake-raises-serum-uric-acid 2026-07-17 weekly https://priors.science/q/fxr-agonists-cause-dose-dependent-pruritus-and-ldl-elevation-in-n 2026-07-17 weekly https://priors.science/q/gabapentin-and-pregabalin-have-equivalent-neuropathic-pain-effica 2026-07-17 weekly https://priors.science/q/gabapentinoids-provide-minimal-benefit-for-non-neuropathic-chroni 2026-07-17 weekly https://priors.science/q/galcanezumab-prevents-episodic-cluster-headache-attacks 2026-07-17 weekly https://priors.science/q/genotype-guided-p2y12-selection-reduces-bleeding-without-increasi 2026-07-17 weekly https://priors.science/q/gepants-relieve-acute-migraine-attacks 2026-07-17 weekly https://priors.science/q/glofitamab-achieves-durable-complete-responses-in-relapsed-large 2026-07-17 weekly https://priors.science/q/glp-1-drugs-like-ozempic-reduce-alcohol-cravings 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-adversely-affect-bone-mineral-density-or 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-are-associated-with-a-reduced-incidence-o 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-cause-a-sustained-increase-in-resting-hea 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-have-significantly-lower-rates-of-hypogly 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-improve-disease-free-survival-or-reduce-r 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-improve-or-stabilise-cognitive-function-i 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-improve-ovulation-rates-and-natural-pregn 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-improve-psoriasis-severity-scores-in-pati 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-improve-testosterone-levels-and-male-repr 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-increase-the-overall-risk-of-gastrointest 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-increase-the-risk-of-gallbladder-and-bili 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-increase-the-risk-of-suicidal-ideation-or 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-modulate-mesolimbic-reward-circuitry-redu 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-or-tirzepatide-can-achieve-type-2-diabete 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-preserve-cerebral-glucose-metabolism-and 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-produce-clinically-meaningful-weight-loss 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-provide-renal-protection-and-slow-the-pro 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-albuminuria-in-diabetic-ckd 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-all-cause-mortality-in-patients-wi 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-cardiovascular-events-in-patients 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-cardiovascular-events-in-patients-2 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-hba1c-by-1-0-2-0-percentage-points 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-hospitalisations-for-heart-failure 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-kidney-outcomes-independent-of-gly 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-liver-fat-and-improve-histological 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-major-adverse-cardiovascular-event 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-neuroinflammation-by-suppressing-m 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-nicotine-cravings-and-support-smok 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-opioid-or-stimulant-use-in-patient 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-pain-and-fatigue-symptoms-in-patie 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-peripheral-arterial-disease-events 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-recurrence-of-atrial-fibrillation 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-serious-liver-events-risk-in-t2d 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-the-risk-of-developing-parkinson-s 2026-07-17 weekly https://priors.science/q/glp-1-receptor-agonists-reduce-the-risk-of-pancreatic-cancer-in-p 2026-07-17 weekly https://priors.science/q/glucocorticoid-monotherapy-frequently-relapses-during-dose-taperi 2026-07-17 weekly https://priors.science/q/glucocorticoid-use-exceeding-7-5-mg-day-prednisone-equivalent-for 2026-07-17 weekly https://priors.science/q/green-tea-catechins-modestly-reduce-body-weight 2026-07-17 weekly https://priors.science/q/guselkumab-achieves-acr20-in-about-60-percent-of-biologic-naive-p 2026-07-17 weekly https://priors.science/q/guselkumab-maintains-pasi-90-through-two-years-of-continuous-dosi 2026-07-17 weekly https://priors.science/q/gut-microbiota-metabolise-polyphenols-into-bioactive-compounds 2026-07-17 weekly https://priors.science/q/h1-antihistamines-reduce-urticaria-symptoms-vs-placebo 2026-07-17 weekly https://priors.science/q/habitual-artificial-sweetener-intake-is-associated-with-weight-ga 2026-07-17 weekly https://priors.science/q/habitual-caffeine-use-blunts-its-ergogenic-effect 2026-07-17 weekly https://priors.science/q/haematologic-response-depth-predicts-cardiac-organ-response-and-s 2026-07-17 weekly https://priors.science/q/heavy-alcohol-consumption-causes-liver-cirrhosis 2026-07-17 weekly https://priors.science/q/hepatic-steatosis-grade-is-not-an-independent-predictor-of-mortal 2026-07-17 weekly https://priors.science/q/her2-low-represents-a-biologically-distinct-and-actionable-therap 2026-07-17 weekly https://priors.science/q/her2-targeted-therapy-is-active-in-her2-amplified-metastatic-colo 2026-07-17 weekly https://priors.science/q/hif-phi-agents-achieve-haemoglobin-targets-non-inferior-to-esas-i 2026-07-17 weekly https://priors.science/q/hif-phi-agents-improve-iron-utilisation-without-supplementation-i 2026-07-17 weekly https://priors.science/q/high-added-sugar-intake-increases-cardiovascular-disease-risk 2026-07-17 weekly https://priors.science/q/high-added-sugar-intake-raises-serum-triglycerides 2026-07-17 weekly https://priors.science/q/high-added-sugar-intake-worsens-insulin-resistance 2026-07-17 weekly https://priors.science/q/high-baseline-total-ige-predicts-complete-omalizumab-response-in 2026-07-17 weekly https://priors.science/q/high-dose-corticosteroids-are-effective-as-first-line-management 2026-07-17 weekly https://priors.science/q/high-dose-dha-raises-ldl-cholesterol 2026-07-17 weekly https://priors.science/q/high-dose-systemic-aav-gene-therapy-carries-a-risk-of-serious-and 2026-07-17 weekly https://priors.science/q/high-dose-vitamin-d-increases-fall-risk-in-older-adults 2026-07-17 weekly https://priors.science/q/high-fr-expression-predicts-mirvetuximab-benefit-in-platinum-resi 2026-07-17 weekly https://priors.science/q/high-intensity-statins-reduce-mace-in-acute-coronary-syndrome-pat 2026-07-17 weekly https://priors.science/q/high-intensity-statins-reduce-mace-more-than-moderate-intensity 2026-07-17 weekly https://priors.science/q/high-intensity-statins-reduce-mace-more-than-moderate-intensity-i 2026-07-17 weekly https://priors.science/q/high-interferon-gene-signature-score-at-baseline-enriches-for-res 2026-07-17 weekly https://priors.science/q/high-sugar-intake-raises-blood-pressure 2026-07-17 weekly https://priors.science/q/high-total-ige-predicts-complete-omalizumab-response-in-csu 2026-07-17 weekly https://priors.science/q/high-tumour-infiltrating-lymphocyte-til-density-and-an-inflamed-i 2026-07-17 weekly https://priors.science/q/high-tumour-mutational-burden-10-mutations-mb-is-associated-with 2026-07-17 weekly https://priors.science/q/higher-daily-water-intake-improves-general-health-outcomes 2026-07-17 weekly https://priors.science/q/higher-dietary-fibre-intake-reduces-all-cause-mortality 2026-07-17 weekly https://priors.science/q/higher-dietary-fibre-intake-reduces-cardiovascular-disease-risk 2026-07-17 weekly https://priors.science/q/higher-dietary-fibre-intake-reduces-colorectal-cancer-risk 2026-07-17 weekly https://priors.science/q/higher-dietary-fibre-intake-reduces-type-2-diabetes-incidence 2026-07-17 weekly https://priors.science/q/higher-fibre-intake-promotes-satiety-and-modest-weight-loss 2026-07-17 weekly https://priors.science/q/higher-flavonoid-intake-lowers-cardiovascular-disease-mortality 2026-07-17 weekly https://priors.science/q/higher-flavonoid-intake-slows-cognitive-decline 2026-07-17 weekly https://priors.science/q/higher-haemoglobin-targets-with-esas-increase-cardiovascular-risk 2026-07-17 weekly https://priors.science/q/higher-magnesium-intake-is-associated-with-greater-bone-density 2026-07-17 weekly https://priors.science/q/higher-magnesium-intake-reduces-stroke-risk 2026-07-17 weekly https://priors.science/q/higher-magnesium-intake-reduces-type-2-diabetes-risk 2026-07-17 weekly https://priors.science/q/higher-protein-intake-attenuates-age-related-loss-of-muscle-mass 2026-07-17 weekly https://priors.science/q/higher-serum-bicarbonate-within-normal-range-reduces-ckd-progress 2026-07-17 weekly https://priors.science/q/higher-ultra-processed-food-intake-increases-all-cause-mortality 2026-07-17 weekly https://priors.science/q/higher-ultra-processed-food-intake-increases-cardiovascular-disea 2026-07-17 weekly https://priors.science/q/higher-ultra-processed-food-intake-increases-colorectal-cancer-ri 2026-07-17 weekly https://priors.science/q/higher-ultra-processed-food-intake-increases-depression-risk 2026-07-17 weekly https://priors.science/q/higher-ultra-processed-food-intake-increases-hypertension-risk 2026-07-17 weekly https://priors.science/q/higher-ultra-processed-food-intake-increases-overall-cancer-risk 2026-07-17 weekly https://priors.science/q/higher-ultra-processed-food-intake-increases-type-2-diabetes-risk 2026-07-17 weekly https://priors.science/q/higher-ultra-processed-food-intake-promotes-weight-gain-and-obesi 2026-07-17 weekly https://priors.science/q/higher-ultra-processed-food-intake-raises-systemic-inflammation-m 2026-07-17 weekly https://priors.science/q/higher-water-intake-reduces-recurrent-kidney-stone-formation 2026-07-17 weekly https://priors.science/q/hipec-at-interval-debulking-improves-os-in-advanced-ovarian-cance 2026-07-17 weekly https://priors.science/q/hiv-cure-strategies-targeting-the-latent-reservoir-including-shoc 2026-07-17 weekly https://priors.science/q/hla-class-i-heterozygosity-at-the-patient-level-is-associated-wit 2026-07-17 weekly https://priors.science/q/hla-cw6-positivity-predicts-superior-ustekinumab-response-in-plaq 2026-07-17 weekly https://priors.science/q/homocysteine-lowering-b-vitamins-reduce-major-cardiovascular-even 2026-07-17 weekly https://priors.science/q/homocysteine-lowering-b-vitamins-reduce-stroke-risk 2026-07-17 weekly https://priors.science/q/how-much-weight-can-you-lose-on-tirzepatide-mounjaro-zepbound 2026-07-17 weekly https://priors.science/q/hrd-testing-identifies-parp-inhibitor-benefit-beyond-germline-brc 2026-07-17 weekly https://priors.science/q/hsct-carries-significant-treatment-related-mortality-in-ssc 2026-07-17 weekly https://priors.science/q/hsct-improves-event-free-survival-vs-cyclophosphamide-in-dcssc 2026-07-17 weekly https://priors.science/q/hsd17b13-loss-of-function-allele-attenuates-pnpla3-driven-fibrosi 2026-07-17 weekly https://priors.science/q/hydroxychloroquine-continuation-during-pregnancy-reduces-sle-dise 2026-07-17 weekly https://priors.science/q/hydroxychloroquine-reduces-the-rate-of-disease-flares-and-should 2026-07-17 weekly https://priors.science/q/hydroxychloroquine-use-is-associated-with-reduced-risk-of-thrombo 2026-07-17 weekly https://priors.science/q/hydroxychloroquine-use-is-independently-associated-with-improved 2026-07-17 weekly https://priors.science/q/hydroxychloroquine-whole-blood-concentration-monitoring-identifie 2026-07-17 weekly https://priors.science/q/hyperkalemia-leads-to-inappropriate-acei-and-arb-discontinuation 2026-07-17 weekly https://priors.science/q/hyperphosphataemia-independently-predicts-cardiovascular-mortalit 2026-07-17 weekly https://priors.science/q/hyperuricaemia-independently-predicts-ckd-progression 2026-07-17 weekly https://priors.science/q/hypohydration-above-two-percent-body-mass-impairs-endurance-perfo 2026-07-17 weekly https://priors.science/q/ici-monotherapy-has-minimal-efficacy-in-alk-nsclc 2026-07-17 weekly https://priors.science/q/icosapent-ethyl-reduces-cardiovascular-events-in-high-risk-patien 2026-07-17 weekly https://priors.science/q/ics-withdrawal-increases-exacerbations-in-low-eosinophil-copd 2026-07-17 weekly https://priors.science/q/idecabtagene-vicleucel-ide-cel-demonstrates-clinically-meaningful 2026-07-17 weekly https://priors.science/q/igg-cleaving-endopeptidases-can-degrade-anti-aav-neutralizing-ant 2026-07-17 weekly https://priors.science/q/il-1-beta-inhibition-reduces-cardiovascular-events-in-high-hscrp 2026-07-17 weekly https://priors.science/q/il-13-inhibitors-improve-quality-of-life-in-atopic-dermatitis 2026-07-17 weekly https://priors.science/q/il-17-inhibitors-increase-inflammatory-bowel-disease-risk-versus 2026-07-17 weekly https://priors.science/q/il-17a-inhibitors-achieve-superior-pasi-90-versus-ustekinumab 2026-07-17 weekly https://priors.science/q/il-23-inhibitors-have-a-more-favourable-safety-profile-than-jak-i 2026-07-17 weekly https://priors.science/q/il-23p19-inhibitors-sustain-pasi-90-at-six-months-after-planned-w 2026-07-17 weekly https://priors.science/q/il-6-independently-predicts-mace-in-coronary-patients 2026-07-17 weekly https://priors.science/q/il-6-inhibition-reduces-mace-in-ckd-patients-with-elevated-hscrp 2026-07-17 weekly https://priors.science/q/il-6-receptor-blockade-with-tocilizumab-is-an-effective-treatment 2026-07-17 weekly https://priors.science/q/iloprost-reduces-raynaud-attacks-and-digital-ulcer-burden-in-ssc 2026-07-17 weekly https://priors.science/q/immunologically-cold-tumours-with-absent-or-low-til-infiltration 2026-07-17 weekly https://priors.science/q/implantable-cardioverter-defibrillator-implantation-for-primary-p 2026-07-17 weekly https://priors.science/q/in-people-with-type-2-diabetes-and-chronic-kidney-disease-egfr-20 2026-07-17 weekly https://priors.science/q/in-people-with-type-2-diabetes-and-established-cardiovascular-dis 2026-07-17 weekly https://priors.science/q/in-people-with-type-2-diabetes-and-obesity-tirzepatide-produces-g 2026-07-17 weekly https://priors.science/q/in-vivo-crispr-ttr-editing-reduces-serum-ttr-by-more-than-90 2026-07-17 weekly https://priors.science/q/inclisiran-biannual-dosing-durably-reduces-ldl-c 2026-07-17 weekly https://priors.science/q/increased-water-intake-slows-chronic-kidney-disease-progression 2026-07-17 weekly https://priors.science/q/infection-prevention-and-control-measures-contact-precautions-env 2026-07-17 weekly https://priors.science/q/infliximab-and-adalimumab-induce-remission-in-moderate-to-severe 2026-07-17 weekly https://priors.science/q/inhaled-corticosteroids-increase-pneumonia-risk-in-copd 2026-07-17 weekly https://priors.science/q/inhaled-dnase-dornase-alfa-reduces-sputum-viscosity-and-decreases 2026-07-17 weekly https://priors.science/q/inhaled-hypertonic-saline-improves-mucociliary-clearance-and-redu 2026-07-17 weekly https://priors.science/q/inhaled-tobramycin-and-aztreonam-reduce-pseudomonas-aeruginosa-sp 2026-07-17 weekly https://priors.science/q/inhaled-treprostinil-improves-6mwd-in-ph-ild 2026-07-17 weekly https://priors.science/q/initial-creatine-weight-gain-reflects-water-retention 2026-07-17 weekly https://priors.science/q/integrase-inhibitors-particularly-dolutegravir-and-bictegravir-ar 2026-07-17 weekly https://priors.science/q/integrase-strand-transfer-inhibitor-insti-resistance-is-uncommon 2026-07-17 weekly https://priors.science/q/intense-pulsed-light-improves-meibomian-gland-function-in-dry-eye 2026-07-17 weekly https://priors.science/q/intense-pulsed-light-reduces-dry-eye-symptoms-in-mgd 2026-07-17 weekly https://priors.science/q/intensive-blood-pressure-reduction-increases-acute-kidney-injury 2026-07-17 weekly https://priors.science/q/intensive-blood-pressure-target-reduces-cardiovascular-events-in 2026-07-17 weekly https://priors.science/q/intensive-bp-control-reduces-stroke-in-type-2-diabetes 2026-07-17 weekly https://priors.science/q/intensive-bp-lowering-preserves-cardiovascular-benefit-in-frail-e 2026-07-17 weekly https://priors.science/q/intensive-glycaemic-control-targeting-hba1c-below-7-0-reduces-the 2026-07-17 weekly https://priors.science/q/intensive-multifactorial-treatment-targeting-glucose-blood-pressu 2026-07-17 weekly https://priors.science/q/intensive-sbp-reduction-below-120-reduces-major-cardiovascular-ev 2026-07-17 weekly https://priors.science/q/intensive-systolic-blood-pressure-below-120-mmhg-reduces-ckd-prog 2026-07-17 weekly https://priors.science/q/interleukin-6-receptor-inhibitors-achieve-acr50-responses-as-mono 2026-07-17 weekly https://priors.science/q/intermittent-fasting-lowers-hba1c-in-type-2-diabetes 2026-07-17 weekly https://priors.science/q/intralesional-corticosteroids-are-effective-for-patchy-alopecia-a 2026-07-17 weekly https://priors.science/q/intranasal-esketamine-plus-an-antidepressant-reduces-depressive-s 2026-07-17 weekly https://priors.science/q/intrathecal-administration-of-tofersen-achieves-sufficient-cns-pe 2026-07-17 weekly https://priors.science/q/intrathecal-immunoglobulin-synthesis-induced-by-tofersen-is-manag 2026-07-17 weekly https://priors.science/q/intrathecal-tofersen-causes-csf-pleocytosis-in-the-majority-of-tr 2026-07-17 weekly https://priors.science/q/intrathecal-tofersen-reduces-csf-sod1-protein-levels-in-a-dose-de 2026-07-17 weekly https://priors.science/q/intravenous-antibiotic-combinations-targeting-pseudomonas-aerugin 2026-07-17 weekly https://priors.science/q/intravenous-cgrp-infusion-triggers-migraine-attacks-in-migraineur 2026-07-17 weekly https://priors.science/q/intravenous-epoprostenol-improves-survival-in-severe-pah 2026-07-17 weekly https://priors.science/q/intravenous-iron-outperforms-oral-iron-in-inflammatory-bowel-dise 2026-07-17 weekly https://priors.science/q/intravenous-iron-raises-haemoglobin-faster-than-oral-iron 2026-07-17 weekly https://priors.science/q/intravenous-iron-reduces-heart-failure-hospitalisation-in-iron-de 2026-07-17 weekly https://priors.science/q/intravenous-iron-reduces-low-birthweight-versus-oral-iron 2026-07-17 weekly https://priors.science/q/intravenous-iron-supplementation-does-not-reduce-all-cause-mortal 2026-07-17 weekly https://priors.science/q/intravenous-iron-supplementation-reduces-heart-failure-hospitalis 2026-07-17 weekly https://priors.science/q/intravenous-ketamine-produces-rapid-antidepressant-response-in-tr 2026-07-17 weekly https://priors.science/q/intravesical-bcg-immunotherapy-is-superior-to-intravesical-chemot 2026-07-17 weekly https://priors.science/q/io-and-parp-inhibitor-combinations-show-modest-activity-in-ovaria 2026-07-17 weekly https://priors.science/q/ipilimumab-achieves-durable-long-term-survival-in-a-subset-of-adv 2026-07-17 weekly https://priors.science/q/ipilimumab-causes-a-distinct-spectrum-of-immune-toxicity-includin 2026-07-17 weekly https://priors.science/q/ipilimumab-improves-overall-survival-in-previously-treated-advanc 2026-07-17 weekly https://priors.science/q/ipragliflozin-improves-nash-fibrosis-in-70-6-versus-22-2-of-t2d-p 2026-07-17 weekly https://priors.science/q/iron-supplementation-improves-endurance-in-non-anaemic-athletes 2026-07-17 weekly https://priors.science/q/iron-supplementation-reduces-fatigue-in-non-anaemic-iron-deficien 2026-07-17 weekly https://priors.science/q/itepekimab-anti-il-33-reduces-asthma-exacerbation-rates-in-patien 2026-07-17 weekly https://priors.science/q/ivacaftor-monotherapy-produces-sustained-improvements-in-fev1-swe 2026-07-17 weekly https://priors.science/q/ixekizumab-achieves-pasi-100-in-about-35-to-40-percent 2026-07-17 weekly https://priors.science/q/ixekizumab-achieves-superior-acr50-versus-adalimumab-in-biologic 2026-07-17 weekly https://priors.science/q/jak-inhibitor-cardiovascular-risk-in-atopic-dermatitis-is-age-dep 2026-07-17 weekly https://priors.science/q/jak-inhibitors-achieve-acr50-and-das28-remission-rates-comparable 2026-07-17 weekly https://priors.science/q/jak-inhibitors-are-associated-with-increased-risk-of-herpes-zoste 2026-07-17 weekly https://priors.science/q/jak-inhibitors-carry-elevated-thromboembolic-risk-in-atopic-derma 2026-07-17 weekly https://priors.science/q/jak-inhibitors-demonstrate-dose-dependent-efficacy-in-atopic-derm 2026-07-17 weekly https://priors.science/q/jak-inhibitors-increase-herpes-zoster-risk-in-alopecia-areata 2026-07-17 weekly https://priors.science/q/jak-inhibitors-increase-mace-risk-in-alopecia-areata 2026-07-17 weekly https://priors.science/q/jak-inhibitors-increase-venous-thromboembolism-risk-versus-tnf-in 2026-07-17 weekly https://priors.science/q/ketamine-assisted-tapering-reduces-pain-during-opioid-withdrawal 2026-07-17 weekly https://priors.science/q/ketogenic-diet-reduces-seizure-frequency-in-drug-resistant-epilep 2026-07-17 weekly https://priors.science/q/ketogenic-diets-lower-triglycerides-and-raise-hdl-cholesterol 2026-07-17 weekly https://priors.science/q/ketogenic-diets-produce-greater-short-term-weight-loss-than-low-f 2026-07-17 weekly https://priors.science/q/ketogenic-diets-raise-ldl-cholesterol-in-a-subset-of-individuals 2026-07-17 weekly https://priors.science/q/ketogenic-diets-reduce-lean-muscle-mass-alongside-fat-loss 2026-07-17 weekly https://priors.science/q/ketogenic-weight-loss-advantage-over-low-fat-diets-narrows-by-twe 2026-07-17 weekly https://priors.science/q/kl-6-serum-levels-predict-ipf-disease-severity-and-progression 2026-07-17 weekly https://priors.science/q/lama-laba-dual-bronchodilation-improves-lung-function-over-monoth 2026-07-17 weekly https://priors.science/q/lama-laba-reduces-exacerbations-compared-with-laba-ics 2026-07-17 weekly https://priors.science/q/lama-reduce-exacerbations-versus-placebo-in-moderate-to-severe-co 2026-07-17 weekly https://priors.science/q/lasmiditan-relieves-acute-migraine-attacks 2026-07-17 weekly https://priors.science/q/late-meal-timing-worsens-glycemic-control 2026-07-17 weekly https://priors.science/q/ldl-c-lowering-with-statins-reduces-cardiovascular-events 2026-07-17 weekly https://priors.science/q/ldl-c-target-attainment-in-secondary-prevention-is-suboptimal 2026-07-17 weekly https://priors.science/q/lebrikizumab-achieves-easi-75-in-moderate-to-severe-atopic-dermat 2026-07-17 weekly https://priors.science/q/lecanemab-slows-ad-decline 2026-07-17 weekly https://priors.science/q/lecanemab-slows-clinical-decline-in-early-alzheimer-s-disease 2026-07-17 weekly https://priors.science/q/left-bundle-branch-pacing-achieves-superior-left-ventricular-elec 2026-07-17 weekly https://priors.science/q/left-ventricular-assist-device-therapy-as-destination-therapy-imp 2026-07-17 weekly https://priors.science/q/lenacapavir-every-6-months-subcutaneous-injection-in-combination 2026-07-17 weekly https://priors.science/q/lenvatinib-is-non-inferior-to-sorafenib-for-overall-survival-in-h 2026-07-17 weekly https://priors.science/q/levetiracetam-is-non-inferior-to-lamotrigine-in-focal-epilepsy 2026-07-17 weekly https://priors.science/q/levodopa-remains-the-most-effective-symptomatic-treatment-for-par 2026-07-17 weekly https://priors.science/q/lifestyle-intervention-achieves-nash-resolution-in-only-16-of-pat 2026-07-17 weekly https://priors.science/q/lifitegrast-5-improves-symptom-scores-in-dry-eye-disease 2026-07-17 weekly https://priors.science/q/lifitegrast-5-reduces-inferior-corneal-staining-in-dry-eye 2026-07-17 weekly https://priors.science/q/ligelizumab-is-non-inferior-to-omalizumab-in-chronic-spontaneous 2026-07-17 weekly https://priors.science/q/liquid-biopsy-shows-lower-sensitivity-for-alk-and-ros1-fusions 2026-07-17 weekly https://priors.science/q/liraglutide-3-mg-daily-achieves-mean-body-weight-reduction-of-5-8 2026-07-17 weekly https://priors.science/q/liraglutide-reduces-the-risk-of-major-adverse-cardiovascular-even 2026-07-17 weekly https://priors.science/q/liver-transaminase-elevation-is-a-common-typically-manageable-adv 2026-07-17 weekly https://priors.science/q/liver-transplantation-within-milan-criteria-yields-best-long-term 2026-07-17 weekly https://priors.science/q/long-acting-cabotegravir-rilpivirine-every-2-months-is-non-inferi 2026-07-17 weekly https://priors.science/q/long-acting-injectable-lenacapavir-every-6-months-is-highly-effec 2026-07-17 weekly https://priors.science/q/long-acting-lipoglycopeptides-reduce-hospital-stay-versus-standar 2026-07-17 weekly https://priors.science/q/long-covid-in-children-and-adolescents-follows-a-generally-milder 2026-07-17 weekly https://priors.science/q/long-sleep-duration-associates-with-higher-diabetes-risk 2026-07-17 weekly https://priors.science/q/long-term-bisphosphonate-use-increases-atypical-femoral-fracture 2026-07-17 weekly https://priors.science/q/long-term-dupilumab-maintains-efficacy-over-52-weeks 2026-07-17 weekly https://priors.science/q/long-term-metformin-use-lowers-vitamin-b12-levels 2026-07-17 weekly https://priors.science/q/long-term-opioid-therapy-induces-hyperalgesia-in-chronic-pain 2026-07-17 weekly https://priors.science/q/long-term-stimulant-use-does-not-reliably-prevent-academic-occupa 2026-07-17 weekly https://priors.science/q/long-term-tpo-receptor-agonist-use-is-associated-with-bone-marrow 2026-07-17 weekly https://priors.science/q/lorlatinib-achieves-superior-intracranial-control-vs-second-gener 2026-07-17 weekly https://priors.science/q/lorlatinib-causes-higher-hyperlipidemia-rates-than-second-generat 2026-07-17 weekly https://priors.science/q/lorlatinib-improves-pfs-vs-alectinib-in-alk-nsclc 2026-07-17 weekly https://priors.science/q/lorlatinib-is-associated-with-cns-adverse-effects 2026-07-17 weekly https://priors.science/q/lorlatinib-third-generation-alk-ros1-tki-demonstrates-superior-pr 2026-07-17 weekly https://priors.science/q/loss-of-function-mutations-in-the-jak1-jak2-or-ifn-signalling-pat 2026-07-17 weekly https://priors.science/q/low-caffeine-doses-improve-endurance-performance 2026-07-17 weekly https://priors.science/q/low-carbohydrate-diets-enable-type-2-diabetes-remission 2026-07-17 weekly https://priors.science/q/low-carbohydrate-diets-improve-glycaemic-control-in-type-2-diabet 2026-07-17 weekly https://priors.science/q/low-dose-methotrexate-does-not-reduce-cardiovascular-events-in-at 2026-07-17 weekly https://priors.science/q/low-dose-naltrexone-may-provide-symptomatic-benefit-in-long-covid 2026-07-17 weekly https://priors.science/q/low-dose-naltrexone-reduces-pain-in-fibromyalgia 2026-07-17 weekly https://priors.science/q/low-risk-status-at-follow-up-improves-pah-survival 2026-07-17 weekly https://priors.science/q/low-serum-bicarbonate-independently-predicts-ckd-progression 2026-07-17 weekly https://priors.science/q/low-tau-predicts-greater-benefit 2026-07-17 weekly https://priors.science/q/lower-achieved-ldl-cholesterol-is-associated-with-greater-cardiov 2026-07-17 weekly https://priors.science/q/lowering-blood-pressure-below-standard-target-reduces-proteinuria 2026-07-17 weekly https://priors.science/q/lumacaftor-ivacaftor-dual-combination-produces-modest-fev1-improv 2026-07-17 weekly https://priors.science/q/lung-clearance-index-lci-is-a-more-sensitive-measure-of-early-cf 2026-07-17 weekly https://priors.science/q/lung-transplantation-significantly-extends-survival-in-ipf-versus 2026-07-17 weekly https://priors.science/q/macitentan-improves-haemodynamics-in-portopulmonary-hypertension 2026-07-17 weekly https://priors.science/q/macitentan-reduces-clinical-worsening-in-ssc-pah 2026-07-17 weekly https://priors.science/q/macitentan-reduces-morbidity-and-mortality-in-pah 2026-07-17 weekly https://priors.science/q/macitentan-tadalafil-combination-improves-6mwd-in-pah 2026-07-17 weekly https://priors.science/q/magnesium-supplementation-improves-glycaemic-control-in-diabetes 2026-07-17 weekly https://priors.science/q/magnesium-supplementation-improves-sleep-quality 2026-07-17 weekly https://priors.science/q/magnesium-supplementation-reduces-migraine-frequency 2026-07-17 weekly https://priors.science/q/magnesium-supplementation-reduces-nocturnal-leg-cramps 2026-07-17 weekly https://priors.science/q/major-bleeding-post-acs-independently-predicts-30-day-mortality 2026-07-17 weekly https://priors.science/q/mao-b-inhibitors-rasagiline-selegiline-safinamide-provide-motor-b 2026-07-17 weekly https://priors.science/q/maternal-omega-3-supplementation-reduces-preterm-birth 2026-07-17 weekly https://priors.science/q/maternal-vitamin-b12-supplementation-improves-infant-neurodevelop 2026-07-17 weekly https://priors.science/q/medical-cannabis-causes-cognitive-adverse-effects-at-therapeutic 2026-07-17 weekly https://priors.science/q/medical-cannabis-reduces-chronic-pain-compared-to-placebo 2026-07-17 weekly https://priors.science/q/memantine-improves-cognition-in-moderate-to-severe-alzheimer-s-di 2026-07-17 weekly https://priors.science/q/mepolizumab-reduces-exacerbations-in-eosinophilic-copd 2026-07-17 weekly https://priors.science/q/met-exon-14-skipping-mutations-define-a-targetable-nsclc-subset-w 2026-07-17 weekly https://priors.science/q/metformin-remains-an-effective-first-line-glucose-lowering-agent 2026-07-17 weekly https://priors.science/q/methotrexate-has-comparable-long-term-efficacy-to-cyclosporin-in 2026-07-17 weekly https://priors.science/q/methotrexate-plus-corticosteroids-achieves-31-complete-alopecia-a 2026-07-17 weekly https://priors.science/q/methylphenidate-and-amphetamine-based-stimulants-are-the-most-eff 2026-07-17 weekly https://priors.science/q/microvascular-invasion-predicts-early-recurrence-and-poor-surviva 2026-07-17 weekly https://priors.science/q/microwave-ablation-has-equivalent-efficacy-to-rfa-for-small-hcc-t 2026-07-17 weekly https://priors.science/q/midlife-cardiovascular-risk-factor-control-reduces-later-dementia 2026-07-17 weekly https://priors.science/q/migraine-is-associated-with-increased-depression-risk 2026-07-17 weekly https://priors.science/q/mild-dehydration-impairs-cognitive-performance-and-mood 2026-07-17 weekly https://priors.science/q/mineralocorticoid-receptor-antagonists-reduce-all-cause-mortality 2026-07-17 weekly https://priors.science/q/mirikizumab-achieves-clinical-remission-in-patients-with-moderate 2026-07-17 weekly https://priors.science/q/mirikizumab-induces-and-maintains-clinical-remission-in-patients 2026-07-17 weekly https://priors.science/q/mirvetuximab-soravtansine-improves-os-in-platinum-resistant-ovari 2026-07-17 weekly https://priors.science/q/mmf-has-fewer-adverse-events-than-cyclophosphamide-in-ssc-ild 2026-07-17 weekly https://priors.science/q/mmf-is-non-inferior-to-cyclophosphamide-for-ssc-ild 2026-07-17 weekly https://priors.science/q/moderate-alcohol-consumption-reduces-cardiovascular-disease-risk 2026-07-17 weekly https://priors.science/q/moderate-statin-plus-ezetimibe-matches-high-intensity-statin 2026-07-17 weekly https://priors.science/q/moderate-to-severe-psoriasis-is-an-independent-risk-factor-for-ca 2026-07-17 weekly https://priors.science/q/modern-pah-therapy-has-substantially-improved-long-term-survival 2026-07-17 weekly https://priors.science/q/more-than-50-of-people-with-obesity-treated-with-semaglutide-2-4 2026-07-17 weekly https://priors.science/q/more-than-one-third-of-people-with-obesity-treated-with-tirzepati 2026-07-17 weekly https://priors.science/q/most-baricitinib-aa-responders-relapse-after-treatment-withdrawal 2026-07-17 weekly https://priors.science/q/most-patients-with-glucocorticoid-induced-osteoporosis-remain-unt 2026-07-17 weekly https://priors.science/q/mosunetuzumab-induces-high-complete-response-rates-in-relapsed-fo 2026-07-17 weekly https://priors.science/q/motor-benefits-from-onasemnogene-abeparvovec-are-durable-beyond-f 2026-07-17 weekly https://priors.science/q/mra-use-is-associated-with-reduced-mortality-in-attr-cardiomyopat 2026-07-17 weekly https://priors.science/q/mre-outperforms-transient-elastography-for-fibrosis-staging-in-na 2026-07-17 weekly https://priors.science/q/mrna-and-gene-therapy-approaches-targeting-cftr-restoration-in-cl 2026-07-17 weekly https://priors.science/q/msi-h-dmmr-status-is-a-predictive-biomarker-for-neoadjuvant-immun 2026-07-17 weekly https://priors.science/q/msi-h-dmmr-status-is-the-most-validated-pan-tumour-predictive-bio 2026-07-17 weekly https://priors.science/q/mss-microsatellite-stable-colorectal-cancer-has-clinically-neglig 2026-07-17 weekly https://priors.science/q/muc5b-rs35705950-is-the-dominant-genetic-susceptibility-locus-for 2026-07-17 weekly https://priors.science/q/muc5b-rs35705950-variant-paradoxically-improves-ipf-survival 2026-07-17 weekly https://priors.science/q/multidisciplinary-clinic-care-prolongs-survival-in-motor-neurone 2026-07-17 weekly https://priors.science/q/multidomain-lifestyle-intervention-slows-cognitive-decline-in-at 2026-07-17 weekly https://priors.science/q/multitarget-therapy-combining-mycophenolate-mofetil-a-calcineurin 2026-07-17 weekly https://priors.science/q/mycophenolate-mofetil-achieves-equivalent-or-superior-induction-r 2026-07-17 weekly https://priors.science/q/mycophenolate-mofetil-is-superior-to-azathioprine-for-maintenance 2026-07-17 weekly https://priors.science/q/nadofaragene-firadenovec-gene-therapy-achieves-durable-complete-r 2026-07-17 weekly https://priors.science/q/nafld-affects-approximately-25-of-the-global-adult-population 2026-07-17 weekly https://priors.science/q/nafld-fibrosis-score-predicts-long-term-liver-related-mortality 2026-07-17 weekly https://priors.science/q/nav1-8-inhibition-reduces-neuropathic-pain-in-clinical-trials 2026-07-17 weekly https://priors.science/q/nemolizumab-improves-sleep-disturbance-in-atopic-dermatitis-patie 2026-07-17 weekly https://priors.science/q/nemolizumab-reduces-pruritus-in-moderate-to-severe-atopic-dermati 2026-07-17 weekly https://priors.science/q/neoadjuvant-chemotherapy-is-non-inferior-to-primary-debulking-in 2026-07-17 weekly https://priors.science/q/neoadjuvant-cisplatin-based-chemotherapy-before-radical-cystectom 2026-07-17 weekly https://priors.science/q/neoadjuvant-dual-checkpoint-blockade-achieves-high-pathological-c 2026-07-17 weekly https://priors.science/q/neoadjuvant-ici-benefit-in-tnbc-is-agent-specific-and-not-a-class 2026-07-17 weekly https://priors.science/q/neoadjuvant-immunotherapy-yields-high-pathological-complete-respo 2026-07-17 weekly https://priors.science/q/neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant 2026-07-17 weekly https://priors.science/q/nerandomilast-reduces-fvc-decline-in-ipf 2026-07-17 weekly https://priors.science/q/net-clinical-benefit-of-anticoagulation-in-subclinical-af-is-posi 2026-07-17 weekly https://priors.science/q/next-generation-alk-tkis-are-active-in-crizotinib-resistant-imt 2026-07-17 weekly https://priors.science/q/next-generation-alk-tkis-improve-pfs-vs-crizotinib 2026-07-17 weekly https://priors.science/q/next-generation-alk-tkis-reduce-intracranial-progression-vs-crizo 2026-07-17 weekly https://priors.science/q/next-generation-cftr-modulators-vanzacaftor-tezacaftor-deutivacaf 2026-07-17 weekly https://priors.science/q/nintedanib-and-pirfenidone-have-similar-efficacy-in-ipf 2026-07-17 weekly https://priors.science/q/nintedanib-slows-annual-fvc-decline-in-ipf 2026-07-17 weekly https://priors.science/q/nintedanib-slows-fvc-decline-in-ssc-ild 2026-07-17 weekly https://priors.science/q/nintedanib-slows-fvc-decline-with-or-without-mmf 2026-07-17 weekly https://priors.science/q/niraparib-first-line-maintenance-extends-pfs-regardless-of-brca-s 2026-07-17 weekly https://priors.science/q/nis4-blood-panel-detects-at-risk-nash-with-auroc-0-80-to-0-83 2026-07-17 weekly https://priors.science/q/nivolumab-combined-with-chemotherapy-improves-overall-survival-ve 2026-07-17 weekly https://priors.science/q/nivolumab-ipilimumab-shows-durable-responses-in-previously-treate 2026-07-17 weekly https://priors.science/q/nivolumab-plus-ipilimumab-combination-immunotherapy-achieves-appr 2026-07-17 weekly https://priors.science/q/nivolumab-plus-ipilimumab-improves-overall-survival-versus-chemot 2026-07-17 weekly https://priors.science/q/nivolumab-plus-ipilimumab-improves-overall-survival-versus-chemot-2 2026-07-17 weekly https://priors.science/q/nivolumab-plus-ipilimumab-improves-overall-survival-versus-suniti 2026-07-17 weekly https://priors.science/q/nivolumab-plus-ipilimumab-improves-overall-survival-versus-suniti-2 2026-07-17 weekly https://priors.science/q/nivolumab-plus-ipilimumab-improves-survival-versus-pd-1-monothera 2026-07-17 weekly https://priors.science/q/nivolumab-plus-ipilimumab-yields-durable-responses-in-msi-h-color 2026-07-17 weekly https://priors.science/q/no-pharmacological-treatment-has-been-approved-by-any-major-regul 2026-07-17 weekly https://priors.science/q/no-pharmacological-treatment-has-demonstrated-robust-disease-modi 2026-07-17 weekly https://priors.science/q/no-single-biomarker-predicts-immune-checkpoint-inhibitor-benefit 2026-07-17 weekly https://priors.science/q/non-calcium-phosphate-binders-reduce-mortality-in-ckd 2026-07-17 weekly https://priors.science/q/non-hdl-c-predicts-residual-ascvd-risk-beyond-ldl-c 2026-07-17 weekly https://priors.science/q/non-invasive-vagus-nerve-stimulation-reduces-migraine 2026-07-17 weekly https://priors.science/q/non-invasive-ventilation-prolongs-survival-in-motor-neurone-disea 2026-07-17 weekly https://priors.science/q/non-nutritive-sweeteners-acutely-raise-blood-glucose-or-insulin 2026-07-17 weekly https://priors.science/q/non-nutritive-sweeteners-alter-the-human-gut-microbiome 2026-07-17 weekly https://priors.science/q/non-nutritive-sweeteners-increase-appetite-or-later-energy-intake 2026-07-17 weekly https://priors.science/q/nt-probnp-is-an-independent-prognostic-marker-for-mortality-in-at 2026-07-17 weekly https://priors.science/q/ntrk-fusion-positive-nsclc-and-other-solid-tumours-responds-to-tr 2026-07-17 weekly https://priors.science/q/oac-can-be-safely-discontinued-after-successful-af-ablation 2026-07-17 weekly https://priors.science/q/oac-reduces-stroke-risk-in-af-with-moderate-ckd 2026-07-17 weekly https://priors.science/q/obeticholic-acid-25mg-improves-liver-fibrosis-in-23-versus-12-pla 2026-07-17 weekly https://priors.science/q/obinutuzumab-achieves-significant-clinical-and-serological-improv 2026-07-17 weekly https://priors.science/q/obinutuzumab-added-to-standard-therapy-significantly-improves-com 2026-07-17 weekly https://priors.science/q/obstructive-sleep-apnea-increases-insulin-resistance 2026-07-17 weekly https://priors.science/q/oestrogen-withdrawal-triggers-menstrual-migraine 2026-07-17 weekly https://priors.science/q/off-target-bypass-mechanisms-cause-a-substantial-fraction-of-alk 2026-07-17 weekly https://priors.science/q/olaparib-maintenance-extends-pfs-in-brca-mutant-advanced-ovarian 2026-07-17 weekly https://priors.science/q/olaparib-maintenance-extends-pfs-in-platinum-sensitive-recurrent 2026-07-17 weekly https://priors.science/q/olaparib-plus-bevacizumab-improves-pfs-in-hrd-positive-ovarian-ca 2026-07-17 weekly https://priors.science/q/olaparib-significantly-improves-radiographic-progression-free-sur 2026-07-17 weekly https://priors.science/q/omadacycline-and-eravacycline-novel-tetracyclines-provide-activit 2026-07-17 weekly https://priors.science/q/omalizumab-300mg-achieves-complete-response-in-refractory-csu 2026-07-17 weekly https://priors.science/q/omalizumab-anti-ige-reduces-asthma-exacerbations-and-unscheduled 2026-07-17 weekly https://priors.science/q/omalizumab-discontinuation-leads-to-relapse-in-majority-of-csu-pa 2026-07-17 weekly https://priors.science/q/omega-3-fatty-acids-lower-serum-triglycerides 2026-07-17 weekly https://priors.science/q/omega-3-fatty-acids-reduce-rheumatoid-arthritis-activity 2026-07-17 weekly https://priors.science/q/omega-3-supplementation-improves-adhd-symptoms-in-children 2026-07-17 weekly https://priors.science/q/omega-3-supplementation-improves-dry-eye-symptoms 2026-07-17 weekly https://priors.science/q/omega-3-supplementation-increases-atrial-fibrillation-risk 2026-07-17 weekly https://priors.science/q/omega-3-supplementation-reduces-major-depressive-symptoms 2026-07-17 weekly https://priors.science/q/omega-3-supplements-reduce-cardiovascular-mortality 2026-07-17 weekly https://priors.science/q/omega-3-supplements-slow-cognitive-decline-in-older-adults 2026-07-17 weekly https://priors.science/q/onabotulinumtoxina-reduces-headache-days-in-chronic-migraine 2026-07-17 weekly https://priors.science/q/onabotulinumtoxina-reduces-headache-days-in-chronic-migraine-2 2026-07-17 weekly https://priors.science/q/onasemnogene-abeparvovec-produces-clinically-significant-improvem 2026-07-17 weekly https://priors.science/q/onasemnogene-abeparvovec-produces-lower-rates-of-unsatisfactory-c 2026-07-17 weekly https://priors.science/q/once-weekly-insulin-icodec-provides-non-inferior-glycaemic-contro 2026-07-17 weekly https://priors.science/q/once-weekly-semaglutide-1-mg-achieves-superior-hba1c-reduction-co 2026-07-17 weekly https://priors.science/q/opioid-based-therapy-reduces-chronic-cough-burden-in-ipf 2026-07-17 weekly https://priors.science/q/opioid-tapering-improves-pain-outcomes-in-long-term-chronic-pain 2026-07-17 weekly https://priors.science/q/oral-erdafitinib-reduces-recurrence-compared-with-intravesical-ch 2026-07-17 weekly https://priors.science/q/oral-iron-corrects-iron-deficiency-anaemia 2026-07-17 weekly https://priors.science/q/oral-magnesium-supplementation-lowers-blood-pressure 2026-07-17 weekly https://priors.science/q/oral-magnesium-supplementation-reduces-migraine-frequency 2026-07-17 weekly https://priors.science/q/oral-magnesium-supplementation-reduces-migraine-frequency-2 2026-07-17 weekly https://priors.science/q/oral-omega-3-supplementation-does-not-improve-dry-eye-signs 2026-07-17 weekly https://priors.science/q/oral-omega-3-supplementation-does-not-improve-dry-eye-symptoms 2026-07-17 weekly https://priors.science/q/oral-semaglutide-14-mg-daily-reduces-hba1c-by-approximately-1-0-1 2026-07-17 weekly https://priors.science/q/oral-treprostinil-improves-outcomes-in-pah-on-background-therapy 2026-07-17 weekly https://priors.science/q/oral-vitamin-b12-corrects-deficiency-as-effectively-as-intramuscu 2026-07-17 weekly https://priors.science/q/oritavancin-and-dalbavancin-long-acting-lipoglycopeptides-provide 2026-07-17 weekly https://priors.science/q/osimertinib-third-generation-egfr-tki-is-superior-to-first-and-se 2026-07-17 weekly https://priors.science/q/osteoporosis-treatment-prevents-hip-fracture-similarly-in-men-and 2026-07-17 weekly https://priors.science/q/overdrinking-fluids-during-endurance-exercise-causes-exercise-ass 2026-07-17 weekly https://priors.science/q/ozempic-cause-thyroid-cancer 2026-07-17 weekly https://priors.science/q/ozempic-cause-vision-loss-or-naion 2026-07-17 weekly https://priors.science/q/ozempic-or-zepbound-help-sleep-apnoea 2026-07-17 weekly https://priors.science/q/ozempic-prevent-alzheimer-s-or-dementia 2026-07-17 weekly https://priors.science/q/p2y12-monotherapy-after-short-dapt-reduces-bleeding-in-acs-patien 2026-07-17 weekly https://priors.science/q/p2y12-monotherapy-after-short-dapt-reduces-bleeding-without-incre 2026-07-17 weekly https://priors.science/q/pacap-infusion-triggers-migraine-attacks-in-migraineurs 2026-07-17 weekly https://priors.science/q/pah-therapies-are-less-effective-in-ssc-pah 2026-07-17 weekly https://priors.science/q/paroxetine-and-venlafaxine-cause-more-severe-discontinuation-synd 2026-07-17 weekly https://priors.science/q/parp-inhibitor-rechallenge-benefits-patients-in-platinum-sensitiv 2026-07-17 weekly https://priors.science/q/parp-inhibitors-extend-progression-free-survival-in-brca-mutant-a 2026-07-17 weekly https://priors.science/q/patent-foramen-ovale-closure-reduces-migraine 2026-07-17 weekly https://priors.science/q/pathological-complete-response-after-neoadjuvant-ici-plus-chemoth 2026-07-17 weekly https://priors.science/q/pathological-complete-response-after-neoadjuvant-immune-checkpoin 2026-07-17 weekly https://priors.science/q/patisiran-preserves-functional-capacity-and-cardiac-outcomes-in-a 2026-07-17 weekly https://priors.science/q/pcsk9-inhibitors-added-to-statins-reduce-mace-post-acs 2026-07-17 weekly https://priors.science/q/pcsk9-inhibitors-reduce-mace-in-ascvd-patients-on-statin 2026-07-17 weekly https://priors.science/q/pcsk9-inhibitors-substantially-reduce-lp-a-alongside-ldl-c 2026-07-17 weekly https://priors.science/q/pd-l1-combined-positive-score-cps-10-is-a-validated-predictive-bi 2026-07-17 weekly https://priors.science/q/pd-l1-expression-cps-or-ic-scoring-is-a-reliable-predictive-bioma 2026-07-17 weekly https://priors.science/q/pd-l1-expression-is-not-a-reliable-predictive-biomarker-for-ici-b 2026-07-17 weekly https://priors.science/q/pd-l1-expression-scoring-cps-or-tps-is-an-imperfect-predictive-bi 2026-07-17 weekly https://priors.science/q/pd-l1-tumour-proportion-score-tps-50-is-a-validated-predictive-bi 2026-07-17 weekly https://priors.science/q/pegylated-liposomal-doxorubicin-has-established-activity-in-plati 2026-07-17 weekly https://priors.science/q/pembrolizumab-achieves-durable-complete-responses-in-patients-wit 2026-07-17 weekly https://priors.science/q/pembrolizumab-combined-with-platinum-5-fu-chemotherapy-improves-o 2026-07-17 weekly https://priors.science/q/pembrolizumab-demonstrates-clinically-meaningful-antitumour-activ 2026-07-17 weekly https://priors.science/q/pembrolizumab-improves-overall-survival-versus-investigator-choic 2026-07-17 weekly https://priors.science/q/pembrolizumab-improves-progression-free-survival-in-msi-h-metasta 2026-07-17 weekly https://priors.science/q/pembrolizumab-monotherapy-improves-overall-survival-versus-platin 2026-07-17 weekly https://priors.science/q/pembrolizumab-monotherapy-improves-overall-survival-versus-the-ex 2026-07-17 weekly https://priors.science/q/pembrolizumab-monotherapy-is-superior-to-chemotherapy-as-first-li 2026-07-17 weekly https://priors.science/q/pembrolizumab-monotherapy-provides-durable-responses-as-first-lin 2026-07-17 weekly https://priors.science/q/pembrolizumab-plus-chemotherapy-extends-survival-in-pd-l1-high-me 2026-07-17 weekly https://priors.science/q/pembrolizumab-plus-neoadjuvant-chemotherapy-improves-outcomes-in 2026-07-17 weekly https://priors.science/q/pembrolizumab-plus-platinum-pemetrexed-chemotherapy-improves-over 2026-07-17 weekly https://priors.science/q/pembrolizumab-prolongs-overall-survival-compared-with-chemotherap 2026-07-17 weekly https://priors.science/q/people-living-with-hiv-on-effective-art-with-an-undetectable-vira 2026-07-17 weekly https://priors.science/q/people-living-with-hiv-on-stable-art-have-substantially-higher-ra 2026-07-17 weekly https://priors.science/q/percutaneous-laao-is-non-inferior-to-oac-for-stroke-prevention 2026-07-17 weekly https://priors.science/q/perfluorohexyloctane-drops-improve-signs-of-evaporative-dry-eye 2026-07-17 weekly https://priors.science/q/perfluorohexyloctane-is-superior-to-saline-for-mgd-dry-eye 2026-07-17 weekly https://priors.science/q/perioperative-durvalumab-added-to-neoadjuvant-gemcitabine-cisplat 2026-07-17 weekly https://priors.science/q/perioperative-nivolumab-plus-chemotherapy-neoadjuvant-followed-by 2026-07-17 weekly https://priors.science/q/perioperative-pembrolizumab-neoadjuvant-plus-adjuvant-significant 2026-07-17 weekly https://priors.science/q/perioperative-pembrolizumab-plus-chemotherapy-improves-event-free 2026-07-17 weekly https://priors.science/q/persistent-microclots-and-endothelial-dysfunction-are-detectable 2026-07-17 weekly https://priors.science/q/persistent-sars-cov-2-viral-antigen-or-rna-in-tissue-reservoirs-g 2026-07-17 weekly https://priors.science/q/persistently-elevated-anti-double-stranded-dna-antibodies-and-low 2026-07-17 weekly https://priors.science/q/pertuzumab-plus-trastuzumab-improves-pathological-complete-respon 2026-07-17 weekly https://priors.science/q/pertuzumab-plus-trastuzumab-is-first-line-standard-in-metastatic 2026-07-17 weekly https://priors.science/q/phage-therapy-combined-with-antibiotics-outperforms-phage-monothe 2026-07-17 weekly https://priors.science/q/phage-therapy-improves-clinical-outcomes-in-drug-resistant-bacter 2026-07-17 weekly https://priors.science/q/phosphate-binders-reduce-serum-phosphate-in-dialysis-patients 2026-07-17 weekly https://priors.science/q/physical-exercise-reduces-risk-of-cognitive-decline-in-older-adul 2026-07-17 weekly https://priors.science/q/pimavanserin-improves-psychosis-in-parkinson-s-disease-without-wo 2026-07-17 weekly https://priors.science/q/pioglitazone-achieves-nash-resolution-in-51-of-patients-with-diab 2026-07-17 weekly https://priors.science/q/pioglitazone-benefits-extend-to-non-diabetic-patients-with-nash 2026-07-17 weekly https://priors.science/q/pioglitazone-improves-advanced-fibrosis-in-nash-with-odds-ratio-3 2026-07-17 weekly https://priors.science/q/pioglitazone-treatment-causes-weight-gain-averaging-2-5-to-4-8-ki 2026-07-17 weekly https://priors.science/q/pirfenidone-reduces-all-cause-mortality-in-ipf 2026-07-17 weekly https://priors.science/q/plant-and-animal-protein-produce-similar-resistance-training-musc 2026-07-17 weekly https://priors.science/q/plasma-neurofilament-light-chain-elevation-identifies-pre-symptom 2026-07-17 weekly https://priors.science/q/plasma-neurofilament-light-chain-levels-are-elevated-before-sympt 2026-07-17 weekly https://priors.science/q/plasma-neurofilament-light-chain-levels-predict-functional-declin 2026-07-17 weekly https://priors.science/q/plasma-phosphorylated-tau-217-accurately-detects-alzheimer-s-path 2026-07-17 weekly https://priors.science/q/pnpla3-gg-genotype-combined-with-t2d-predicts-highest-cirrhosis-r 2026-07-17 weekly https://priors.science/q/pnpla3-gg-genotype-doubles-cirrhosis-risk-in-nafld-over-20-years 2026-07-17 weekly https://priors.science/q/pnpla3-i148m-is-the-strongest-genetic-risk-factor-for-nafld 2026-07-17 weekly https://priors.science/q/polygenic-risk-scores-predict-hcc-risk-in-nafld-patients 2026-07-17 weekly https://priors.science/q/polyphenol-intake-improves-insulin-sensitivity 2026-07-17 weekly https://priors.science/q/polyphenol-oral-bioavailability-is-low-and-highly-variable 2026-07-17 weekly https://priors.science/q/post-exertional-malaise-pem-worsening-of-symptoms-following-physi 2026-07-17 weekly https://priors.science/q/potent-p2y12-inhibitors-reduce-mace-versus-clopidogrel-post-acs 2026-07-17 weekly https://priors.science/q/prasugrel-increases-major-bleeding-vs-clopidogrel-in-pci-patients 2026-07-17 weekly https://priors.science/q/prasugrel-increases-net-harm-vs-clopidogrel-in-patients-with-prio 2026-07-17 weekly https://priors.science/q/prasugrel-reduces-mace-vs-clopidogrel-in-acs-patients-undergoing 2026-07-17 weekly https://priors.science/q/pre-existing-neutralizing-antibodies-against-aav-serotypes-exclud 2026-07-17 weekly https://priors.science/q/pre-treatment-circulating-tumour-dna-level-does-not-reliably-pred 2026-07-17 weekly https://priors.science/q/pregabalin-reduces-pain-scores-in-diabetic-peripheral-neuropathy 2026-07-17 weekly https://priors.science/q/prenatal-alcohol-exposure-causes-neurodevelopmental-harm 2026-07-17 weekly https://priors.science/q/prenatal-omega-3-improves-child-neurodevelopment 2026-07-17 weekly https://priors.science/q/presymptomatic-treatment-of-sma-with-onasemnogene-abeparvovec-ini 2026-07-17 weekly https://priors.science/q/primary-aldosteronism-is-an-under-diagnosed-cause-of-resistant-hy 2026-07-17 weekly https://priors.science/q/primary-prevention-icd-implantation-reduces-all-cause-mortality-i 2026-07-17 weekly https://priors.science/q/prior-ace-inhibitor-use-worsens-outcomes-in-scleroderma-renal-cri 2026-07-17 weekly https://priors.science/q/probiotic-colonization-of-the-adult-gut-is-transient 2026-07-17 weekly https://priors.science/q/probiotics-increase-gut-microbial-diversity-in-healthy-adults 2026-07-17 weekly https://priors.science/q/probiotics-prevent-antibiotic-associated-diarrhea 2026-07-17 weekly https://priors.science/q/probiotics-reduce-clostridioides-difficile-infection-risk 2026-07-17 weekly https://priors.science/q/probiotics-reduce-depressive-symptoms-in-adults 2026-07-17 weekly https://priors.science/q/probiotics-reduce-irritable-bowel-syndrome-symptom-severity 2026-07-17 weekly https://priors.science/q/probiotics-reduce-upper-respiratory-tract-infection-incidence 2026-07-17 weekly https://priors.science/q/prompt-glucocorticoid-therapy-reduces-permanent-vision-loss-in-gi 2026-07-17 weekly https://priors.science/q/protein-above-1-6-g-per-kg-daily-adds-no-further-muscle 2026-07-17 weekly https://priors.science/q/protein-supplementation-augments-resistance-training-muscle-mass 2026-07-17 weekly https://priors.science/q/protein-supplementation-without-exercise-increase-muscle-mass-in 2026-07-17 weekly https://priors.science/q/psilocybin-reduces-depressive-symptoms-in-treatment-resistant-dep 2026-07-17 weekly https://priors.science/q/psma-pet-ct-imaging-demonstrates-superior-sensitivity-and-specifi 2026-07-17 weekly https://priors.science/q/psychological-stress-commonly-triggers-migraine-attacks 2026-07-17 weekly https://priors.science/q/pten-loss-and-pi3k-akt-pathway-activation-are-associated-with-res 2026-07-17 weekly https://priors.science/q/pulmonary-hypertension-significantly-worsens-ipf-survival-outcome 2026-07-17 weekly https://priors.science/q/pulmonary-rehabilitation-benefits-in-ipf-are-not-sustained-beyond 2026-07-17 weekly https://priors.science/q/pulmonary-rehabilitation-improves-exercise-capacity-in-ipf 2026-07-17 weekly https://priors.science/q/pulmonary-vasodilators-provide-limited-benefit-in-ipf-associated 2026-07-17 weekly https://priors.science/q/punctal-occlusion-improves-symptoms-in-aqueous-deficient-dry-eye 2026-07-17 weekly https://priors.science/q/punctal-plugs-increase-schirmer-test-scores-in-dry-eye 2026-07-17 weekly https://priors.science/q/raas-blockade-provides-no-clear-mortality-benefit-in-acs-with-pre 2026-07-17 weekly https://priors.science/q/raas-blockade-reduces-proteinuria-independent-of-blood-pressure 2026-07-17 weekly https://priors.science/q/radiofrequency-ablation-achieves-curative-outcomes-in-early-stage 2026-07-17 weekly https://priors.science/q/radium-223-dichloride-significantly-improves-overall-survival-in 2026-07-17 weekly https://priors.science/q/ramucirumab-improves-survival-in-hcc-patients-with-elevated-afp 2026-07-17 weekly https://priors.science/q/ras-mutation-predicts-lack-of-anti-egfr-benefit-in-colorectal-can 2026-07-17 weekly https://priors.science/q/reactivation-of-latent-herpesviruses-epstein-barr-virus-cytomegal 2026-07-17 weekly https://priors.science/q/real-time-cgm-improves-time-in-range-70-180-mg-dl-in-people-with 2026-07-17 weekly https://priors.science/q/real-time-continuous-glucose-monitoring-reduces-hba1c-in-people-w 2026-07-17 weekly https://priors.science/q/real-time-continuous-glucose-monitoring-reduces-hypoglycaemia-fre 2026-07-17 weekly https://priors.science/q/real-world-anti-cgrp-effectiveness-mirrors-randomised-trial-outco 2026-07-17 weekly https://priors.science/q/real-world-effectiveness-of-biologics-in-severe-asthma-approximat 2026-07-17 weekly https://priors.science/q/real-world-effectiveness-of-eti-approximates-clinical-trial-outco 2026-07-17 weekly https://priors.science/q/real-world-omalizumab-effectiveness-mirrors-trial-data-in-csu 2026-07-17 weekly https://priors.science/q/rebamipide-improves-goblet-cell-density-in-dry-eye-disease 2026-07-17 weekly https://priors.science/q/reducing-added-sugar-intake-reduces-body-weight 2026-07-17 weekly https://priors.science/q/reducing-hydroxychloroquine-dosing-to-5-mg-kg-real-body-weight-re 2026-07-17 weekly https://priors.science/q/regorafenib-improves-overall-survival-in-sorafenib-tolerant-hcc-a 2026-07-17 weekly https://priors.science/q/relapse-is-common-after-tocilizumab-discontinuation 2026-07-17 weekly https://priors.science/q/remibrutinib-achieves-complete-symptom-control-in-antihistamine-r 2026-07-17 weekly https://priors.science/q/remnant-cholesterol-predicts-cardiovascular-events-despite-statin 2026-07-17 weekly https://priors.science/q/remote-electrical-neuromodulation-aborts-acute-migraine 2026-07-17 weekly https://priors.science/q/renal-denervation-reduces-sbp-in-patients-on-stable-medications 2026-07-17 weekly https://priors.science/q/renin-angiotensin-aldosterone-system-blockade-ace-inhibitors-or-a 2026-07-17 weekly https://priors.science/q/repetitive-transcranial-magnetic-stimulation-reduces-symptoms-in 2026-07-17 weekly https://priors.science/q/replacing-sugar-with-non-nutritive-sweeteners-reduces-body-weight 2026-07-17 weekly https://priors.science/q/repotrectinib-achieves-superior-pfs-in-tki-naive-ros1-nsclc 2026-07-17 weekly https://priors.science/q/repotrectinib-is-active-in-crizotinib-resistant-ros1-nsclc 2026-07-17 weekly https://priors.science/q/resective-surgery-reduces-seizures-in-drug-resistant-temporal-lob 2026-07-17 weekly https://priors.science/q/residual-inflammatory-risk-persists-in-majority-of-statin-treated 2026-07-17 weekly https://priors.science/q/resmetirom-80mg-achieves-nash-resolution-in-25-9-versus-9-7-place 2026-07-17 weekly https://priors.science/q/resmetirom-80mg-improves-fibrosis-by-at-least-one-stage-in-24-2 2026-07-17 weekly https://priors.science/q/resmetirom-is-the-first-fda-approved-treatment-for-non-cirrhotic 2026-07-17 weekly https://priors.science/q/resmetirom-reduces-ldl-cholesterol-as-a-secondary-metabolic-benef 2026-07-17 weekly https://priors.science/q/resumption-of-ici-therapy-rechallenge-after-resolution-of-a-sever 2026-07-17 weekly https://priors.science/q/resveratrol-improves-glycaemic-control-in-type-2-diabetes 2026-07-17 weekly https://priors.science/q/reveal-2-0-accurately-predicts-one-year-survival-in-pah 2026-07-17 weekly https://priors.science/q/rhythm-control-improves-outcomes-in-af-with-preserved-ejection-fr 2026-07-17 weekly https://priors.science/q/riluzole-modestly-prolongs-survival-in-motor-neurone-disease 2026-07-17 weekly https://priors.science/q/risankizumab-achieves-clinical-remission-in-patients-with-moderat 2026-07-17 weekly https://priors.science/q/risankizumab-achieves-superior-endoscopic-remission-compared-to-u 2026-07-17 weekly https://priors.science/q/risankizumab-achieves-superior-pasi-90-versus-ustekinumab-in-plaq 2026-07-17 weekly https://priors.science/q/risankizumab-improves-acr20-and-minimal-disease-activity-versus-p 2026-07-17 weekly https://priors.science/q/ritlecitinib-achieves-salt-20-in-23-of-alopecia-areata-patients 2026-07-17 weekly https://priors.science/q/ritlecitinib-is-effective-for-alopecia-areata-in-adolescents 2026-07-17 weekly https://priors.science/q/rituximab-improves-haemodynamics-and-outcomes-in-ssc-pah 2026-07-17 weekly https://priors.science/q/rituximab-reduces-mrss-in-diffuse-cutaneous-ssc 2026-07-17 weekly https://priors.science/q/rituximab-stabilizes-fvc-decline-in-ssc-ild 2026-07-17 weekly https://priors.science/q/rna-based-ngs-detects-more-fusions-than-dna-based-ngs-in-nsclc 2026-07-17 weekly https://priors.science/q/rna-interference-therapy-reduces-serum-ttr-concentrations-by-more 2026-07-17 weekly https://priors.science/q/roflumilast-reduces-exacerbations-in-severe-chronic-bronchitis-co 2026-07-17 weekly https://priors.science/q/romiplostim-increases-platelet-counts-and-reduces-bleeding-in-chr 2026-07-17 weekly https://priors.science/q/romosozumab-reduces-fracture-risk-more-than-alendronate-in-osteop 2026-07-17 weekly https://priors.science/q/romosozumab-treatment-increases-cardiovascular-adverse-event-risk 2026-07-17 weekly https://priors.science/q/rosiglitazone-does-not-improve-liver-fibrosis-unlike-pioglitazone 2026-07-17 weekly https://priors.science/q/roxadustat-improves-anaemia-in-dialysis-dependent-ckd 2026-07-17 weekly https://priors.science/q/rucaparib-demonstrates-clinically-meaningful-activity-in-mcrpc-pa 2026-07-17 weekly https://priors.science/q/ruxolitinib-cream-provides-rapid-pruritus-reduction-versus-vehicl 2026-07-17 weekly https://priors.science/q/ruxolitinib-cream-reduces-easi-in-mild-to-moderate-atopic-dermati 2026-07-17 weekly https://priors.science/q/saccharin-causes-bladder-cancer-in-humans 2026-07-17 weekly https://priors.science/q/sacituzumab-govitecan-extends-survival-in-pretreated-metastatic-t 2026-07-17 weekly https://priors.science/q/sacituzumab-govitecan-improves-overall-survival-compared-with-che 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-benefits-hfpef-patients-with-ejection-fracti 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-causes-more-symptomatic-hypotension-than-ace 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-does-not-reduce-cv-events-after-acute-myocar 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-does-not-significantly-reduce-primary-outcom 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-does-not-significantly-reduce-the-primary-co 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-improves-health-related-quality-of-life-more 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-is-contraindicated-within-36-hours-of-ace-in 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-reduces-all-cause-mortality-and-heart-failur 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-reduces-all-cause-mortality-versus-enalapril 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-reduces-cv-death-and-hf-hospitalisation-vers 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-reduces-nt-probnp-more-than-acei-in-hfref 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-reverses-left-ventricular-remodelling-more-t 2026-07-17 weekly https://priors.science/q/sacubitril-valsartan-worsen-renal-function-versus-acei-in-hfref 2026-07-17 weekly https://priors.science/q/second-line-ramucirumab-or-aflibercept-extends-survival-in-metast 2026-07-17 weekly https://priors.science/q/secukinumab-achieves-pasi-90-in-about-60-percent-of-patients 2026-07-17 weekly https://priors.science/q/secukinumab-maintains-remission-in-giant-cell-arteritis 2026-07-17 weekly https://priors.science/q/secukinumab-meets-the-asas20-endpoint-in-active-axial-psoriatic-a 2026-07-17 weekly https://priors.science/q/secukinumab-sustains-acr20-response-through-five-years-in-psoriat 2026-07-17 weekly https://priors.science/q/selexipag-reduces-morbidity-and-mortality-in-pulmonary-arterial-h 2026-07-17 weekly https://priors.science/q/selexipag-reduces-morbidity-and-mortality-risk-in-pah 2026-07-17 weekly https://priors.science/q/self-reported-long-covid-symptom-prevalence-substantially-overest 2026-07-17 weekly https://priors.science/q/selpercatinib-selective-ret-inhibitor-achieves-high-objective-res 2026-07-17 weekly https://priors.science/q/semaglutide-0-4mg-achieves-nash-resolution-in-59-versus-17-placeb 2026-07-17 weekly https://priors.science/q/semaglutide-2-4-mg-weekly-achieves-a-mean-body-weight-reduction-o 2026-07-17 weekly https://priors.science/q/semaglutide-2-4-mg-weekly-achieves-mean-body-weight-loss-of-appro 2026-07-17 weekly https://priors.science/q/semaglutide-2-4-mg-weekly-maintains-clinically-meaningful-weight 2026-07-17 weekly https://priors.science/q/semaglutide-2-4-mg-weekly-obesity-dose-achieves-greater-weight-lo 2026-07-17 weekly https://priors.science/q/semaglutide-2-4-mg-weekly-reduces-bmi-by-at-least-15-relative-to 2026-07-17 weekly https://priors.science/q/semaglutide-2-4mg-achieves-nash-resolution-in-62-9-versus-34-3-pl 2026-07-17 weekly https://priors.science/q/semaglutide-2-4mg-improves-liver-fibrosis-in-36-8-versus-22-4-pla 2026-07-17 weekly https://priors.science/q/semaglutide-does-not-improve-fibrosis-in-nash-related-compensated 2026-07-17 weekly https://priors.science/q/semaglutide-increases-the-risk-of-diabetic-retinopathy-complicati 2026-07-17 weekly https://priors.science/q/semaglutide-reduces-kidney-disease-progression-in-ckd 2026-07-17 weekly https://priors.science/q/semaglutide-reduces-liver-fat-and-alt-in-non-diabetic-nafld-patie 2026-07-17 weekly https://priors.science/q/semaglutide-reduces-the-risk-of-major-adverse-kidney-events-in-pe 2026-07-17 weekly https://priors.science/q/semaglutide-slows-egfr-decline-in-ckd-irrespective-of-diabetes-st 2026-07-17 weekly https://priors.science/q/sequential-ici-followed-by-alk-tki-increases-serious-toxicity 2026-07-17 weekly https://priors.science/q/sequential-use-of-enzalutamide-after-abiraterone-or-vice-versa-in 2026-07-17 weekly https://priors.science/q/serious-neurological-adverse-events-including-myelitis-and-myelor 2026-07-17 weekly https://priors.science/q/serious-statin-hepatotoxicity-is-rare-and-routine-liver-enzyme-mo 2026-07-17 weekly https://priors.science/q/sertraline-and-paroxetine-reduce-ptsd-symptom-severity-versus-pla 2026-07-17 weekly https://priors.science/q/serum-drug-level-monitoring-improves-tnf-alpha-inhibitor-outcomes 2026-07-17 weekly https://priors.science/q/serum-neurofilament-light-chain-is-a-validated-biomarker-of-neuro 2026-07-17 weekly https://priors.science/q/sglt2-inhibitor-dapagliflozin-improves-hepatic-steatosis-in-t2d-n 2026-07-17 weekly https://priors.science/q/sglt2-inhibitor-initiation-during-or-immediately-after-hospitalis 2026-07-17 weekly https://priors.science/q/sglt2-inhibitor-kidney-benefit-extends-to-ckd-patients-without-di 2026-07-17 weekly https://priors.science/q/sglt2-inhibitor-kidney-benefit-is-greatest-in-patients-with-high 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-are-associated-with-euglycaemic-diabetic-ketoaci 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-are-associated-with-increased-risk-of-diabetic-k 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-benefit-post-acs-patients-without-diabetes 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-do-not-reduce-mace-in-t2d-without-established-cv 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-do-not-significantly-reduce-cv-mortality-in-hfpe 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-increase-the-risk-of-genital-mycotic-infections 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-lower-nocturnal-bp-in-diabetic-hypertension 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-albuminuria-in-ckd 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-albuminuria-progression-in-people-with-ty 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-all-cause-mortality-in-hfref 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-alt-and-fib-4-in-nafld-patients 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-cardiovascular-death-and-heart-failure-ho 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-cardiovascular-death-in-ckd 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-ckd-progression-in-type-2-diabetes 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-composite-kidney-outcomes-in-ckd 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-cv-death-and-hf-hospitalisation-in-hfpef 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-cv-death-and-hf-hospitalisation-in-hfref 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-hba1c-by-approximately-0-7-1-0-percentage 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-heart-failure-hospitalization-post-acs 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-hospitalisation-for-heart-failure-in-ckd 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-hospitalisation-for-heart-failure-in-peop 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-hospitalisation-for-heart-failure-in-t2d 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-kidney-outcomes-in-non-diabetic-ckd 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-mace-in-t2d-with-established-cardiovascul 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-reduce-the-risk-of-heart-failure-hospitalisation 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-slow-egfr-decline-in-advanced-ckd 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-slow-kidney-disease-progression-and-reduce-kidne 2026-07-17 weekly https://priors.science/q/sglt2-inhibitors-slow-progression-of-chronic-kidney-disease-reduc 2026-07-17 weekly https://priors.science/q/shift-work-increases-metabolic-syndrome-risk 2026-07-17 weekly https://priors.science/q/short-dapt-is-noninferior-to-12-month-dapt-for-ischemic-events-po 2026-07-17 weekly https://priors.science/q/short-sleep-duration-increases-obesity-risk 2026-07-17 weekly https://priors.science/q/short-sleep-duration-increases-type-2-diabetes-risk 2026-07-17 weekly https://priors.science/q/shorter-diabetes-duration-lower-baseline-hba1c-and-absence-of-ins 2026-07-17 weekly https://priors.science/q/single-agent-checkpoint-inhibitors-have-limited-activity-in-ovari 2026-07-17 weekly https://priors.science/q/single-inhaler-triple-therapy-improves-adherence-over-multiple-in 2026-07-17 weekly https://priors.science/q/single-lipiflow-treatment-benefits-persist-at-12-months 2026-07-17 weekly https://priors.science/q/sleep-extension-reduces-energy-intake-in-adults 2026-07-17 weekly https://priors.science/q/sleep-restriction-increases-daily-energy-intake 2026-07-17 weekly https://priors.science/q/sleep-restriction-lowers-leptin-and-raises-ghrelin 2026-07-17 weekly https://priors.science/q/snris-are-more-effective-than-ssris-for-pain-symptoms-comorbid-wi 2026-07-17 weekly https://priors.science/q/snris-reduce-pain-scores-in-fibromyalgia 2026-07-17 weekly https://priors.science/q/sodium-bicarbonate-supplementation-slows-ckd-progression-in-metab 2026-07-17 weekly https://priors.science/q/sodium-ingestion-improves-endurance-exercise-performance 2026-07-17 weekly https://priors.science/q/sodium-phenylbutyrate-taurursodiol-prolongs-survival-in-motor-neu 2026-07-17 weekly https://priors.science/q/sodium-restriction-lowers-bp-regardless-of-hypertension-diagnosis 2026-07-17 weekly https://priors.science/q/sodium-supplementation-during-prolonged-exercise-prevents-exercis 2026-07-17 weekly https://priors.science/q/soluble-fibre-intake-lowers-ldl-cholesterol 2026-07-17 weekly https://priors.science/q/sorafenib-improves-overall-survival-in-advanced-hcc-versus-best-s 2026-07-17 weekly https://priors.science/q/sotatercept-improves-6-minute-walk-distance-in-pah 2026-07-17 weekly https://priors.science/q/sotatercept-improves-exercise-capacity-added-to-pah-therapy 2026-07-17 weekly https://priors.science/q/sotatercept-reduces-clinical-worsening-in-high-risk-pah 2026-07-17 weekly https://priors.science/q/sotorasib-kras-g12c-inhibitor-provides-clinically-meaningful-obje 2026-07-17 weekly https://priors.science/q/specific-dietary-factors-trigger-migraine-attacks 2026-07-17 weekly https://priors.science/q/spironolactone-outperforms-other-agents-as-4th-line-in-resistant 2026-07-17 weekly https://priors.science/q/ssc-pah-has-worse-prognosis-than-idiopathic-pah 2026-07-17 weekly https://priors.science/q/ssri-use-in-late-pregnancy-is-associated-with-neonatal-adaptation 2026-07-17 weekly https://priors.science/q/ssris-and-snris-are-effective-first-line-treatments-in-generalise 2026-07-17 weekly https://priors.science/q/ssris-and-snris-cause-sexual-dysfunction-in-30-40-of-treated-pati 2026-07-17 weekly https://priors.science/q/ssris-and-snris-reduce-depressive-symptoms-versus-placebo-in-mdd 2026-07-17 weekly https://priors.science/q/ssris-are-safe-and-reduce-depression-in-patients-after-myocardial 2026-07-17 weekly https://priors.science/q/ssris-increase-suicidal-ideation-in-children-and-adolescents 2026-07-17 weekly https://priors.science/q/ssris-reduce-symptoms-in-obsessive-compulsive-disorder 2026-07-17 weekly https://priors.science/q/statin-absolute-benefit-is-small-in-low-cardiovascular-risk-prima 2026-07-17 weekly https://priors.science/q/statin-associated-muscle-symptoms-occur-in-5-10-of-patients-in-cl 2026-07-17 weekly https://priors.science/q/statin-cardiovascular-benefit-extends-to-patients-with-diabetes-m 2026-07-17 weekly https://priors.science/q/statin-cardiovascular-benefit-is-primarily-mediated-through-ldl-c 2026-07-17 weekly https://priors.science/q/statin-myopathy-risk-is-dose-dependent-and-highest-with-simvastat 2026-07-17 weekly https://priors.science/q/statin-therapy-reduces-all-cause-mortality-in-ckd-stages-3-to-4 2026-07-17 weekly https://priors.science/q/statin-therapy-reduces-cardiovascular-risk-in-primary-prevention 2026-07-17 weekly https://priors.science/q/statins-do-not-reduce-all-cause-mortality-in-primary-prevention 2026-07-17 weekly https://priors.science/q/statins-do-not-reduce-cardiovascular-outcomes-in-systolic-heart-f 2026-07-17 weekly https://priors.science/q/statins-have-limited-cardiovascular-benefit-in-dialysis-dependent 2026-07-17 weekly https://priors.science/q/statins-have-pleiotropic-anti-inflammatory-effects-independent-of 2026-07-17 weekly https://priors.science/q/statins-increase-the-risk-of-new-onset-type-2-diabetes-mellitus 2026-07-17 weekly https://priors.science/q/statins-reduce-cardiovascular-events-in-high-risk-primary-prevent 2026-07-17 weekly https://priors.science/q/statins-reduce-cardiovascular-events-in-patients-with-chronic-kid 2026-07-17 weekly https://priors.science/q/statins-reduce-mace-and-mortality-in-patients-with-established-ca 2026-07-17 weekly https://priors.science/q/statins-reduce-major-cardiovascular-events-in-non-dialysis-ckd 2026-07-17 weekly https://priors.science/q/step-up-dosing-reduces-severe-cytokine-release-syndrome-with-bisp 2026-07-17 weekly https://priors.science/q/stewardship-programmes-reduce-multidrug-resistant-organism-rates 2026-07-17 weekly https://priors.science/q/stimulant-medications-produce-small-increases-in-heart-rate-and-b 2026-07-17 weekly https://priors.science/q/stimulant-medications-reduce-adhd-symptoms-in-adults-with-compara 2026-07-17 weekly https://priors.science/q/stopping-acei-and-arbs-in-advanced-ckd-does-not-improve-renal-out 2026-07-17 weekly https://priors.science/q/stopping-raas-inhibitor-does-not-slow-advanced-ckd-progression 2026-07-17 weekly https://priors.science/q/subclinical-af-exceeding-24-hours-increases-thromboembolic-risk 2026-07-17 weekly https://priors.science/q/subcutaneous-semaglutide-0-5-mg-and-1-mg-weekly-reduce-the-risk-o 2026-07-17 weekly https://priors.science/q/subcutaneous-semaglutide-reduces-all-cause-mortality-in-people-wi 2026-07-17 weekly https://priors.science/q/sugar-sweetened-beverage-intake-increases-body-weight-and-adiposi 2026-07-17 weekly https://priors.science/q/sugar-sweetened-beverage-intake-increases-type-2-diabetes-risk 2026-07-17 weekly https://priors.science/q/sulphonylureas-are-associated-with-significantly-higher-rates-of 2026-07-17 weekly https://priors.science/q/sumatriptan-naproxen-combination-outperforms-either-monotherapy 2026-07-17 weekly https://priors.science/q/supervised-rehabilitation-programmes-including-breathing-exercise 2026-07-17 weekly https://priors.science/q/surgical-antireflux-treatment-does-not-slow-ipf-progression 2026-07-17 weekly https://priors.science/q/surgical-laao-during-cardiac-surgery-reduces-stroke-incidence 2026-07-17 weekly https://priors.science/q/surgical-resection-is-the-preferred-curative-treatment-for-resect 2026-07-17 weekly https://priors.science/q/sweetener-induced-microbiome-changes-impair-human-glucose-toleran 2026-07-17 weekly https://priors.science/q/switch-from-tenofovir-disoproxil-fumarate-tdf-to-tenofovir-alafen 2026-07-17 weekly https://priors.science/q/switching-between-anti-cgrp-antibodies-benefits-migraine-non-resp 2026-07-17 weekly https://priors.science/q/systemic-corticosteroids-shorten-recovery-in-acute-copd-exacerbat 2026-07-17 weekly https://priors.science/q/systemic-lupus-erythematosus-is-independently-associated-with-a-3 2026-07-17 weekly https://priors.science/q/systemic-pulse-corticosteroids-achieve-75-response-in-alopecia-ar 2026-07-17 weekly https://priors.science/q/t-dm1-improves-survival-in-her2-positive-residual-disease-after-n 2026-07-17 weekly https://priors.science/q/t-dxd-achieves-responses-in-her2-amplified-colorectal-cancer 2026-07-17 weekly https://priors.science/q/t-dxd-achieves-responses-in-her2-mutant-non-small-cell-lung-cance 2026-07-17 weekly https://priors.science/q/t-dxd-has-clinically-meaningful-cns-activity-in-her2-positive-bre 2026-07-17 weekly https://priors.science/q/t-dxd-improves-survival-in-her2-low-breast-cancer 2026-07-17 weekly https://priors.science/q/t-dxd-is-superior-to-t-dm1-in-previously-treated-her2-positive-me 2026-07-17 weekly https://priors.science/q/tace-combined-with-rfa-improves-outcomes-over-rfa-alone-in-hcc 2026-07-17 weekly https://priors.science/q/tace-is-the-standard-treatment-for-intermediate-stage-hcc 2026-07-17 weekly https://priors.science/q/tafamidis-reduces-all-cause-mortality-and-cardiovascular-hospital 2026-07-17 weekly https://priors.science/q/tafamidis-reduces-mortality-and-hospitalisations-in-both-attrwt-a 2026-07-17 weekly https://priors.science/q/tafamidis-stabilises-or-reduces-left-ventricular-mass-and-preserv 2026-07-17 weekly https://priors.science/q/talquetamab-targeting-gprc5d-produces-responses-in-relapsed-myelo 2026-07-17 weekly https://priors.science/q/tapentadol-reduces-neuropathic-pain-with-less-gi-burden-than-oxyc 2026-07-17 weekly https://priors.science/q/targeted-rna-interference-substantially-lowers-circulating-lp-a 2026-07-17 weekly https://priors.science/q/tc-99m-pyp-scintigraphy-has-high-specificity-for-diagnosing-attr 2026-07-17 weekly https://priors.science/q/teclistamab-induces-deep-responses-in-triple-class-refractory-mul 2026-07-17 weekly https://priors.science/q/temporal-artery-ultrasound-halo-sign-diagnoses-giant-cell-arterit 2026-07-17 weekly https://priors.science/q/tezepelumab-anti-tslp-reduces-asthma-exacerbation-rates-across-ty 2026-07-17 weekly https://priors.science/q/tezepelumab-reduces-blood-eosinophils-feno-and-ige-confirming-ups 2026-07-17 weekly https://priors.science/q/tezepelumab-reduces-exacerbations-in-copd 2026-07-17 weekly https://priors.science/q/thc-dominant-cannabis-reduces-pain-more-than-cbd-only-formulation 2026-07-17 weekly https://priors.science/q/the-cardiovascular-and-malignancy-safety-signal-from-the-oral-sur 2026-07-17 weekly https://priors.science/q/the-combination-of-sglt2-inhibitor-arni-beta-blocker-and-mra-prov 2026-07-17 weekly https://priors.science/q/the-dfs-and-os-benefit-of-adjuvant-ici-in-rcc-after-nephrectomy-i 2026-07-17 weekly https://priors.science/q/the-heartmate-3-centrifugal-flow-lvad-is-superior-to-axial-flow-d 2026-07-17 weekly https://priors.science/q/the-incidence-of-long-covid-is-substantially-lower-following-omic 2026-07-17 weekly https://priors.science/q/the-national-amyloidosis-centre-staging-system-stratifies-prognos 2026-07-17 weekly https://priors.science/q/the-rheumatoid-arthritis-jak-cardiovascular-signal-is-definitivel 2026-07-17 weekly https://priors.science/q/the-survival-benefit-of-primary-prevention-icd-implantation-in-hf 2026-07-17 weekly https://priors.science/q/therapeutic-drug-monitoring-guides-dose-optimisation-and-improves 2026-07-17 weekly https://priors.science/q/there-is-no-safe-level-of-alcohol-consumption 2026-07-17 weekly https://priors.science/q/thermal-pulsation-therapy-improves-meibomian-gland-dysfunction-sy 2026-07-17 weekly https://priors.science/q/ticagrelor-increases-major-bleeding-vs-clopidogrel-in-acs-patient 2026-07-17 weekly https://priors.science/q/ticagrelor-reduces-mace-and-mortality-vs-clopidogrel-in-acs 2026-07-17 weekly https://priors.science/q/tight-blood-pressure-control-targeting-below-130-80-mmhg-reduces 2026-07-17 weekly https://priors.science/q/time-restricted-eating-improves-blood-lipid-profile 2026-07-17 weekly https://priors.science/q/time-restricted-eating-is-feasible-with-high-adherence-and-no-ser 2026-07-17 weekly https://priors.science/q/time-restricted-eating-is-not-superior-to-calorie-restriction-for 2026-07-17 weekly https://priors.science/q/time-restricted-eating-reduces-body-weight-versus-unrestricted-ea 2026-07-17 weekly https://priors.science/q/time-restricted-eating-reduces-lean-muscle-mass 2026-07-17 weekly https://priors.science/q/time-restricted-eating-reduces-visceral-and-total-fat-mass 2026-07-17 weekly https://priors.science/q/time-restricted-eating-reduces-weight-independent-of-calorie-inta 2026-07-17 weekly https://priors.science/q/tirzepatide-15-mg-weekly-achieves-mean-body-weight-reduction-of-a 2026-07-17 weekly https://priors.science/q/tirzepatide-15-mg-weekly-produces-significantly-greater-percentag 2026-07-17 weekly https://priors.science/q/tirzepatide-15mg-achieves-mash-resolution-in-62-versus-10-placebo 2026-07-17 weekly https://priors.science/q/tirzepatide-achieves-fibrosis-improvement-in-51-versus-30-placebo 2026-07-17 weekly https://priors.science/q/tirzepatide-achieves-superior-hba1c-reduction-compared-with-injec 2026-07-17 weekly https://priors.science/q/tirzepatide-added-to-basal-insulin-achieves-greater-hba1c-and-wei 2026-07-17 weekly https://priors.science/q/tirzepatide-dual-gip-glp-1-receptor-agonist-achieves-greater-weig 2026-07-17 weekly https://priors.science/q/tirzepatide-has-a-better-ocular-safety-profile-than-semaglutide-w 2026-07-17 weekly https://priors.science/q/tirzepatide-reduces-major-adverse-liver-outcomes-versus-dpp4-inhi 2026-07-17 weekly https://priors.science/q/tisagenlecleucel-produces-durable-remissions-in-relapsed-refracto 2026-07-17 weekly https://priors.science/q/tisagenlecleucel-produces-high-rates-of-complete-remission-in-pae 2026-07-17 weekly https://priors.science/q/tnf-alpha-inhibitor-biosimilars-are-equivalent-in-efficacy-and-sa 2026-07-17 weekly https://priors.science/q/tnf-alpha-inhibitors-achieve-pasi-75-response-in-moderate-to-seve 2026-07-17 weekly https://priors.science/q/tnf-alpha-inhibitors-are-associated-with-increased-lymphoma-risk 2026-07-17 weekly https://priors.science/q/tnf-alpha-inhibitors-are-contraindicated-in-moderate-to-severe-he 2026-07-17 weekly https://priors.science/q/tnf-alpha-inhibitors-are-effective-in-ankylosing-spondylitis-and 2026-07-17 weekly https://priors.science/q/tnf-alpha-inhibitors-are-effective-in-psoriatic-arthritis 2026-07-17 weekly https://priors.science/q/tnf-alpha-inhibitors-can-trigger-demyelinating-disease-and-are-co 2026-07-17 weekly https://priors.science/q/tnf-alpha-inhibitors-combined-with-methotrexate-are-superior-to-m 2026-07-17 weekly https://priors.science/q/tnf-alpha-inhibitors-increase-the-risk-of-serious-infections-incl 2026-07-17 weekly https://priors.science/q/tnf-alpha-inhibitors-inhibit-radiographic-joint-damage-progressio 2026-07-17 weekly https://priors.science/q/tnf-alpha-inhibitors-maintain-steroid-free-remission-in-ulcerativ 2026-07-17 weekly https://priors.science/q/tnf-alpha-inhibitors-reduce-signs-and-symptoms-of-rheumatoid-arth 2026-07-17 weekly https://priors.science/q/tnf-inhibitors-achieve-acr50-responses-and-inhibit-radiographic-p 2026-07-17 weekly https://priors.science/q/tocilizumab-preserves-fvc-in-ssc-ild-vs-placebo 2026-07-17 weekly https://priors.science/q/tocilizumab-reduces-mrss-in-early-diffuse-cutaneous-ssc 2026-07-17 weekly https://priors.science/q/tocilizumab-sustains-glucocorticoid-free-remission-in-giant-cell 2026-07-17 weekly https://priors.science/q/tofacitinib-increases-cardiovascular-events-versus-tnf-inhibitors 2026-07-17 weekly https://priors.science/q/tofacitinib-induces-and-maintains-clinical-remission-in-patients 2026-07-17 weekly https://priors.science/q/tofacitinib-significantly-improves-acr20-versus-placebo-in-psoria 2026-07-17 weekly https://priors.science/q/tofersen-does-not-demonstrate-a-statistically-significant-effect 2026-07-17 weekly https://priors.science/q/tofersen-prevents-or-delays-als-symptom-onset-in-pre-symptomatic 2026-07-17 weekly https://priors.science/q/tofersen-reduces-neurofilament-levels-in-sod1-motor-neurone-disea 2026-07-17 weekly https://priors.science/q/tofersen-reduces-plasma-neurofilament-light-chain-levels-in-sod1 2026-07-17 weekly https://priors.science/q/tofersen-reduces-sod1-protein-through-rnase-h-mediated-degradatio 2026-07-17 weekly https://priors.science/q/tofersen-slows-functional-decline-in-sod1-als-patients-over-12-mo 2026-07-17 weekly https://priors.science/q/tofersen-treatment-is-associated-with-prolonged-survival-in-sod1 2026-07-17 weekly https://priors.science/q/tofogliflozin-improves-liver-histology-including-fibrosis-in-nafl 2026-07-17 weekly https://priors.science/q/topical-cyclosporine-reduces-corneal-staining-in-dry-eye-disease 2026-07-17 weekly https://priors.science/q/topiramate-reduces-episodic-migraine-attack-frequency 2026-07-17 weekly https://priors.science/q/topiramate-reduces-episodic-migraine-attack-frequency-2 2026-07-17 weekly https://priors.science/q/total-ige-level-and-allergen-sensitisation-pattern-are-required-t 2026-07-17 weekly https://priors.science/q/tpo-receptor-agonists-allow-splenectomy-avoidance-in-steroid-refr 2026-07-17 weekly https://priors.science/q/tpo-receptor-agonists-are-associated-with-an-increased-risk-of-th 2026-07-17 weekly https://priors.science/q/tpo-receptor-agonists-do-not-improve-outcomes-in-myelodysplastic 2026-07-17 weekly https://priors.science/q/tpo-receptor-agonists-reduce-clinically-significant-bleeding-even 2026-07-17 weekly https://priors.science/q/tralokinumab-achieves-iga-clearance-in-moderate-to-severe-atopic 2026-07-17 weekly https://priors.science/q/transmitted-drug-resistance-tdr-to-instis-is-increasing-in-some-s 2026-07-17 weekly https://priors.science/q/trastuzumab-improves-survival-in-her2-positive-gastric-cancer 2026-07-17 weekly https://priors.science/q/trastuzumab-resistance-commonly-involves-pi3k-pathway-activation 2026-07-17 weekly https://priors.science/q/tremelimumab-as-monotherapy-has-limited-antitumour-activity-compa 2026-07-17 weekly https://priors.science/q/tremelimumab-plus-durvalumab-improves-overall-survival-versus-sor 2026-07-17 weekly https://priors.science/q/tremelimumab-plus-durvalumab-stride-regimen-improves-overall-surv 2026-07-17 weekly https://priors.science/q/triple-therapy-confers-no-benefit-over-dual-in-low-risk-pah 2026-07-17 weekly https://priors.science/q/triple-therapy-reduces-all-cause-mortality-in-copd 2026-07-17 weekly https://priors.science/q/triple-therapy-reduces-exacerbations-versus-dual-therapy-in-copd 2026-07-17 weekly https://priors.science/q/triptans-relieve-acute-migraine-pain 2026-07-17 weekly https://priors.science/q/tucatinib-plus-trastuzumab-plus-capecitabine-improves-survival-af 2026-07-17 weekly https://priors.science/q/tucatinib-reduces-intracranial-progression-in-her2-positive-breas 2026-07-17 weekly https://priors.science/q/tumour-mutational-burden-assessment-improves-prediction-of-ici-re 2026-07-17 weekly https://priors.science/q/tumour-mutational-burden-high-status-tmb-h-predicts-ici-benefit-i 2026-07-17 weekly https://priors.science/q/tumour-mutational-burden-predicts-benefit-from-ctla-4-inhibitor-c 2026-07-17 weekly https://priors.science/q/tumour-mutational-burden-tmb-high-10-mut-mb-predicts-pembrolizuma 2026-07-17 weekly https://priors.science/q/two-drug-regimens-dolutegravir-lamivudine-dolutegravir-rilpivirin 2026-07-17 weekly https://priors.science/q/type-2-diabetes-remission-achieved-through-intensive-lifestyle-in 2026-07-17 weekly https://priors.science/q/ultra-processed-diets-increase-energy-intake-in-controlled-feedin 2026-07-17 weekly https://priors.science/q/uncoupling-sweetness-from-calories-disrupts-appetite-regulation 2026-07-17 weekly https://priors.science/q/untargeted-iron-supplementation-increases-infection-risk-in-endem 2026-07-17 weekly https://priors.science/q/upadacitinib-30-mg-daily-significantly-improves-sle-disease-activ 2026-07-17 weekly https://priors.science/q/upadacitinib-achieves-easi-75-versus-placebo-in-atopic-dermatitis 2026-07-17 weekly https://priors.science/q/upadacitinib-achieves-higher-clinical-remission-rates-than-tofaci 2026-07-17 weekly https://priors.science/q/upadacitinib-achieves-higher-easi-75-rates-than-dupilumab-in-atop 2026-07-17 weekly https://priors.science/q/upadacitinib-achieves-higher-rates-of-clinical-remission-than-ved 2026-07-17 weekly https://priors.science/q/upadacitinib-achieves-superior-acr50-versus-placebo-in-tnf-ir-pso 2026-07-17 weekly https://priors.science/q/upadacitinib-induces-and-maintains-clinical-remission-in-patients 2026-07-17 weekly https://priors.science/q/upadacitinib-induces-sustained-remission-in-giant-cell-arteritis 2026-07-17 weekly https://priors.science/q/upadacitinib-matches-or-exceeds-adalimumab-on-acr-response-in-bio 2026-07-17 weekly https://priors.science/q/updosing-h1-antihistamines-fourfold-increases-responder-rate 2026-07-17 weekly https://priors.science/q/upfront-triple-therapy-outperforms-double-therapy-in-pah 2026-07-17 weekly https://priors.science/q/urate-lowering-therapy-reduces-kidney-failure-events-in-hyperuric 2026-07-17 weekly https://priors.science/q/ustekinumab-demonstrates-superior-clinical-remission-to-vedolizum 2026-07-17 weekly https://priors.science/q/ustekinumab-induces-and-maintains-clinical-remission-in-patients 2026-07-17 weekly https://priors.science/q/ustekinumab-is-non-inferior-to-adalimumab-for-clinical-remission 2026-07-17 weekly https://priors.science/q/v142i-variant-attr-cardiomyopathy-has-worse-prognosis-than-wild-t 2026-07-17 weekly https://priors.science/q/vagus-nerve-stimulation-reduces-seizure-frequency-in-drug-resista 2026-07-17 weekly https://priors.science/q/valproate-is-more-effective-than-lamotrigine-in-generalised-epile 2026-07-17 weekly https://priors.science/q/vedolizumab-achieves-clinical-remission-in-patients-with-crohn-s 2026-07-17 weekly https://priors.science/q/vedolizumab-achieves-higher-rates-of-clinical-remission-than-adal 2026-07-17 weekly https://priors.science/q/vedolizumab-subcutaneous-formulation-maintains-remission-with-non 2026-07-17 weekly https://priors.science/q/vegetarians-and-vegans-have-elevated-risk-of-vitamin-b12-deficien 2026-07-17 weekly https://priors.science/q/venlafaxine-causes-dose-dependent-blood-pressure-elevation 2026-07-17 weekly https://priors.science/q/vericiguat-does-not-significantly-reduce-the-composite-of-cardiov 2026-07-17 weekly https://priors.science/q/vericiguat-reduces-the-composite-of-cardiovascular-death-or-heart 2026-07-17 weekly https://priors.science/q/very-low-calorie-diets-800-kcal-day-for-8-or-more-weeks-achieve-t 2026-07-17 weekly https://priors.science/q/very-low-calorie-ketogenic-diets-reduce-visceral-and-liver-fat 2026-07-17 weekly https://priors.science/q/very-low-diastolic-bp-increases-cardiac-events-in-coronary-diseas 2026-07-17 weekly https://priors.science/q/viloxazine-and-guanfacine-are-fda-approved-non-stimulant-alternat 2026-07-17 weekly https://priors.science/q/vitamin-b12-deficiency-causes-reversible-peripheral-neuropathy 2026-07-17 weekly https://priors.science/q/vitamin-b12-supplementation-lowers-plasma-homocysteine 2026-07-17 weekly https://priors.science/q/vitamin-b12-supplementation-prevents-cognitive-decline-in-older-a 2026-07-17 weekly https://priors.science/q/vitamin-c-supplements-do-not-prevent-common-colds 2026-07-17 weekly https://priors.science/q/vitamin-d-analogues-reduce-parathyroid-hormone-in-ckd 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-alone-does-not-reduce-fracture-risk 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-improves-covid-19-clinical-outcomes 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-in-pregnancy-reduces-pre-eclampsia-risk 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-in-pregnancy-reduces-small-for-gestatio 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-increases-bone-mineral-density-in-adult 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-prevents-type-2-diabetes-in-prediabetes 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-reduces-acute-respiratory-infection-ris 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-reduces-all-cause-mortality 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-reduces-asthma-exacerbations 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-reduces-cancer-incidence 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-reduces-cancer-mortality 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-reduces-falls-in-older-adults 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-reduces-fracture-risk-in-general-adults 2026-07-17 weekly https://priors.science/q/vitamin-d-supplementation-reduces-major-cardiovascular-events 2026-07-17 weekly https://priors.science/q/vitamin-d-with-calcium-reduces-hip-fractures-in-institutionalised 2026-07-17 weekly https://priors.science/q/vitamin-e-supplements-do-not-prevent-cardiovascular-events 2026-07-17 weekly https://priors.science/q/voclosporin-added-to-mycophenolate-mofetil-and-low-dose-steroids 2026-07-17 weekly https://priors.science/q/voclosporin-maintains-renal-remission-benefit-at-2-years-without 2026-07-17 weekly https://priors.science/q/vutrisiran-reduces-all-cause-mortality-and-cardiovascular-events 2026-07-17 weekly https://priors.science/q/weekly-paclitaxel-extends-pfs-in-platinum-resistant-ovarian-cance 2026-07-17 weekly https://priors.science/q/weight-reduction-mediates-mash-resolution-with-tirzepatide-treatm 2026-07-17 weekly https://priors.science/q/white-coat-hypertension-increases-cardiovascular-risk-beyond-norm 2026-07-17 weekly https://priors.science/q/women-with-hfref-benefit-from-lower-acei-and-arb-doses-than-guide 2026-07-17 weekly https://priors.science/q/y-90-radioembolization-achieves-comparable-survival-to-tace-in-in 2026-07-17 weekly https://priors.science/q/you-lose-muscle-on-ozempic-or-wegovy 2026-07-17 weekly https://priors.science/q/you-regain-the-weight-after-stopping-ozempic-or-wegovy 2026-07-17 weekly